

Catalytic Enantioselective Synthesis of 3-Piperidines from Arylboronic Acids and Pyridine

Sourabh Mishra, Sedef Karabiyikoglu, Stephen P. Fletcher*

Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, United Kingdom

Supporting Information – Experimental procedures and Data

Table of Contents

1. General Information	2
2. Synthesis of Dihydropyridines.....	3
3. General Procedure for Rh-Catalyzed Cross-Coupling	6
4. Derivatization of Chiral Tetrahydropyridines	54
5. References	59
6. NMR Spectra.....	60

1. General Information

All reactions were carried out in anhydrous solvents with continuous magnetic stirring under an inert argon atmosphere. Heating was performed using DrySyn heating blocks.

Nuclear magnetic resonance (NMR) spectroscopy measurements were carried out at room temperature. ^1H NMR, ^{13}C NMR, ^{19}F NMR, COSY, HSQC, HMBC and NOESY experiments were carried out using Bruker AVIII HD 400 (400/100 MHz) or AVIII HD 400 (500/125 MHz) spectrometers. Chemical shifts (δ) are reported in ppm relative to the residual solvent peak with corresponding coupling constants (J) in Hertz (Hz) and multiplicities (s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet and combinations of these). Assignment follows HSQC, COSY, HMBC or/and NOESY spectra, chemical shift and coupling constant analysis.


Optical rotations ($[\alpha]_{25}^{\text{D}}$) were recorded using a Perkin Elmer-241 Polarimeter. Concentrations (c) are reported in g/100 mL.

Chiral SFC (supercritical fluid chromatography) separations were conducted on a Waters Acquity UPC2 system using Waters Empower software. Solvents used were of HPLC grade (Fisher Scientific, Sigma Aldrich or Rathburn). Chiralpak columns (150x3 mm, particle size 3 μm) were used at 1500 PSI, 30 $^{\circ}\text{C}$, flow: 1.5 mL/min under one of the following gradients- **Gradient 1**: 1% to 30% MeOH in 5 min, 30% to 50% MeOH in 0.5 min, hold 50% MeOH for 2 min; **Gradient 2**: 1% to 50% MeOH in 2 min, hold 50% MeOH for 5 min; **Gradient 3**: 0% to 15% MeOH in 7.5 min


High Resolution Mass spectra were carried out on a Walters BioAccord LC-MS System using Electron spray ionisation (ESI⁺) loop injection MS at the University of Oxford.

Commercially available reagents and ligands were purchased from Sigma Aldrich, Alfa Aesar, Acros Organics, Fluorochem and Strem Chemicals and were used without further purification unless stated otherwise. $[\text{Rh}(\text{cod})\text{OH}]_2$ was bought from Sigma Aldrich. All aryl and heteroarylboronic acids were purchased and used without additional purification unless stated otherwise. Dry solvents were purchased from Thermo ScientificTM, Extra Dry over Molecular Sieve, Stabilized, AcroSealTM and were degassed with argon prior to usage. Deuterated solvents were purchased from Sigma Aldrich.

2. Synthesis of Dihydropyridines




Chloroformate (20 mmol, 1 equiv) was added dropwise under nitrogen to a MeOH solution (50 mL) of NaBH_4 (20.0 mmol), pyridine (20 mmol) at $-78\text{ }^\circ\text{C}$. The reaction was maintained at $-78\text{ }^\circ\text{C}$ for 3 h and then quenched by water (50 ml). The mixture was extracted with Et_2O (30 ml) two times. The combined organic layer was washed with 1N NaOH (two times) followed by 1N HCl (two times) then dried over sodium sulfate. After filtration, the solvents were removed by evaporation. The crude mixture was purified by a short pad of silica gel with acetone/hexane (2% to 10% gradient) as an eluent. The solvent was removed by evaporation under reduced pressure to obtain **1** as white solid. The product was then recrystallized in methanol providing **1** (72% yield) as white crystal.




Phenyl pyridine-1(2H)-carboxylate (1): $^1\text{H NMR}$ (400 MHz, CDCl_3) (2 rotamers): δ (ppm) 7.42 – 7.33 (m, 2H), 7.25 – 7.19 (m, 1H), 7.18 – 7.10 (m, 2H), 6.92 – 6.76 (m, 1H), 5.95 – 5.86 (m, 1H), 5.65 – 5.53 (m, 1H), 5.33 – 5.17 (m, 1H), 4.67 – 4.38 (m, 2H). The spectroscopic data satisfactorily matched previously reported data.^{1,2}

Other 1,2-dihydropyridines S1–S8 were prepared from the corresponding pyridines according to the procedure described above. The spectroscopic data for 1,2-dihydropyridines S1–S8 satisfactorily matched previously reported data.^{1,2} 1,2-dihydropyridines (**S1–S8**) were used immediately in order to prevent decomposition.




A solution of NMe_3BH_3 (5.5 mmol, 1.1 equiv) in MeCN (5 mL) was added dropwise to a flask containing quinoline (5 mmol, 1 equiv) and phenyl chloroformate (6 mmol, 1.2 equiv) in MeCN (5 mL) at -40 °C and stirred for 5 minutes. The reaction was stirred for 10 minutes at room temperature. The product was directly purified by column chromatography on silica gel. The spectroscopic data for Phenyl quinoline-1(2H)-carboxylate (**S9**) satisfactorily matched previously reported data.³




Phenyl 7-methylquinoline-1(2H)-carboxylate (S10): The corresponding compound was prepared following the procedure above using phenyl chloroformate and 7-methylquinoline. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **S10** as white solid (82% yield).

¹H NMR (CDCl_3 , 400 MHz): δ (ppm) 7.50 (dd, $J = 17.4, 4.2$ Hz, 1H), 7.32 (tt, $J = 7.6, 2.2$ Hz, 3H), 7.21 – 7.03 (m, 5H), 6.94 (d, $J = 7.6$ Hz, 1H), 6.72 (dq, $J = 9.7, 1.0$ Hz, 2H), 6.10 (dt, $J = 9.7, 4.2$ Hz, 1H), 4.43 (dd, $J = 4.2, 1.4$ Hz, 3H), 2.32 (s, 3H). **¹³C NMR** (101 MHz, CDCl_3): δ (ppm) 152.7, 151.2, 136.1, 133.9, 129.4, 127.0, 126.9, 126.7, 125.6, 123.7, 122.0, 121.7, 115.4, 43.2, 19.2. **HRMS** (ESI): m/z calcd for $\text{C}_{17}\text{H}_{16}\text{O}_2\text{N}^+$ $[\text{M} + \text{H}]^+$ 266.1176 found 266.1194. **IR** ($\nu_{\text{max}}/\text{cm}^{-1}$) 2361, 1731, 1642, 1608, 1495, 1435, 1408, 1379, 1349, 1257, 1237, 1207, 1082, 1059, 900, 773, 754, 713.



Phenyl-6-methoxyquinoline-1(2H)-carboxylate (S11): The corresponding compound was prepared following general procedure **2** using phenyl chloroformate and 6-methoxyquinoline. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **S11** as white solid (76% yield).


¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.61 (bs, 1H), 7.43 – 7.34 (m, 2H), 7.26 – 7.14 (m, 3H), 6.80 (dd, *J* = 8.9, 2.9 Hz, 1H), 6.68 (d, *J* = 2.9 Hz, 1H), 6.54 (d, *J* = 9.6 Hz, 1H), 6.11 (dt, *J* = 8.8, 3.9 Hz, 1H), 4.53 (s, 2H), 3.81 (s, 2H). **¹³C NMR** (126 MHz, CDCl₃) δ (ppm) 156.8, 151.2, 129.5, 129.4, 128.6, 126.6, 125.6, 124.9, 121.7, 120.2, 115.4, 112.9, 111.4, 55.5, 44.0. **IR** (ν_{max}/cm⁻¹) 2361, 1729, 1593, 1557, 1494, 1463, 1372, 1339, 1281, 1227, 1204, 1163, 1123, 772, 752, 687.



phenyl 6-bromo-7-methylquinoline-1(2H)-carboxylate (S12): The corresponding compound was prepared following general procedure **2** using phenyl chloroformate and 6-bromo-7-methylquinoline. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **S12** as viscous liquid (80% yield).

¹H NMR (CDCl₃, 500 MHz) δ (ppm) 7.64 (bs, 1H), 7.40 (tt, *J* = 7.7, 2.2 Hz, 2H), 7.29 – 7.20 (m, 2H), 7.17 (dt, *J* = 8.9, 1.8 Hz, 2H), 6.47 (d, *J* = 9.6 Hz, 1H), 6.05 (dt, *J* = 9.0, 4.1 Hz, 1H), 4.54 (s, 2H), 2.37 (s, 3H). **¹³C NMR** (126 MHz, CDCl₃) δ (ppm) 152.6, 151.1, 137.2, 135.1, 129.7, 129.5, 127.7, 125.9, 125.5, 121.8, 120.3, 44.0, 23.2. **HRMS** (ESI): *m/z* calcd for C₁₇H₁₅O₂NBr⁺ [M + H]⁺ 344.0281 found 344.0285. **IR** (ν_{max}/cm⁻¹) 2361, 1725, 1595, 1494, 1390, 1365, 1332, 1276, 1231, 1204, 1161, 1048, 1030, 885, 771, 749, 689.


3. General Procedure for Rh-Catalyzed Cross-Coupling



General Procedure A: $[\text{Rh}(\text{cod})\text{OH}]_2$ (6.9 mg, 0.015 mmol, 3 mol%) and (S)-Segphos (21.4 mg, 0.035 mmol, 7 mol%) were added to a 7 mL dram vial equipped with a magnetic stir bar and sealed with a rubber septum. The vial was put under reduced pressure then purged with argon, this was repeated three times. Toluene (0.25 mL), THP (0.25 mL), H_2O (0.25 mL) followed by aq. CsOH (50 wt%, 180 μL , 1 mmol, 2.0 equiv) was added to the vial and the catalyst solution was stirred at 70 °C. After 10 min, boronic acid **2** (1.5 mmol, 3.0 equiv) then dihydropyridine **1** (0.5 mmol, 1 equiv) was added and the resulting mixture was stirred at 70 °C for 20 hours unless stated otherwise. Upon completion of reaction, the mixture was cooled to room temperature and diluted with Et_2O (5 mL) before passing through a plug of SiO_2 . The plug was washed with additional 20 mL of Et_2O and the solvents were removed in vacuo. Purification by flash chromatography afforded the desired product **3**.

Racemates: Racemic samples were synthesized with (\pm)-SegPhos instead of (S)-Segphos.

Upscale: Larger-scale experiments were performed in 5 mmol scale in direct analogy to the general procedure B in a 25 mL round-bottom flask.





Phenyl-(S)-3-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (3a): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 10% acetone/petrol) afforded compound **3a** as viscous liquid (80% yield, 96% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.44 – 7.33 (m, 4H), 7.32 – 7.01 (m, 7H), 5.25 – 5.14 (m, 1H), 4.35 – 4.29 (m, 1H), 3.55 – 3.29 (m, 1H), 3.11 – 3.07 (m, 1H), 2.45 – 2.26 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.3, 151.1, 142.8, 142.7, 129.5, 129.4, 128.9, 128.85, 127.4, 127.3, 127.2, 127.1, 125.7, 125.7, 125.3, 125.0, 121.8, 121.7, 107.9, 107.5, 48.6, 48.0, 38.8, 38.6, 29.5, 29.3.

HRMS (ESI): m/z calcd for C₁₈H₁₈O₂N⁺ [M + H]⁺ 280.1332 found 280.1328.

IR (ν_{max}/cm⁻¹) 1723, 1406, 1362, 1252, 1200, 751, 700, 689.

SFC Conditions: Chiralpak IC; Gradient 1; 99:1 er (major enantiomer t_R = 4.08 min; minor enantiomer t_R = 4.28 min), **98% ee**. [α]_D²⁵ = -41.8 (c = 2.0, CHCl₃).







Phenyl-(S)-3-(p-tolyl)-3,4-dihydropyridine-1(2H)-carboxylate (3b): The corresponding compound was prepared following general procedure **A** using *p*-tolyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 10% acetone/petrol) afforded compound **3b** as white solid (80% yield, 99% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.38 (tdd, *J* = 9.3, 6.3, 1.8 Hz, 2H), 7.26 – 7.00 (m, 8H), 5.27 – 5.10 (m, 1H), 4.36 – 4.25 (m, 1H), 3.53 – 3.23 (m, 1H), 3.18 – 3.00 (m, 1H), 2.44 – 2.27 (m, 5H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.3, 151.1, 139.8, 139.7, 136.8, 136.7, 129.6, 129.5, 129.48, 129.4, 127.2, 127.18, 125.7, 125.6, 125.2, 124.9, 121.8, 121.7, 107.9, 107.5, 48.7, 48.1, 38.3, 38.2, 29.5, 29.4, 21.1.

HRMS (ESI): *m/z* calcd for C₁₉H₂₀O₂N⁺ [M + H]⁺ 294.1489 found 294.1491.

IR (ν_{max}/cm⁻¹) 1724, 1405, 1359, 1251, 1199, 1163, 1074, 974, 813, 751, 728, 689.

SFC Conditions: Chiralpak IE; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 4.31 min; minor enantiomer *t_R* = 4.19 min), **99% ee**. [α]_D²⁵ = -54.5 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(4-(trimethylsilyl)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate


(3c): The corresponding compound was prepared following general procedure **A** using 4-(trimethylsilyl)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (100% petrol to 5% acetone/petrol) afforded compound **3c** as viscous liquid (80% yield, 90% ee).

¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.55 – 7.49 (m, 2H), 7.35 (dt, *J* = 14.3, 8.0 Hz, 2H), 7.29 – 6.97 (m, 6H), 5.23 – 5.12 (m, 1H), 4.31 (dt, *J* = 11.7, 4.8 Hz, 1H), 3.51 – 3.31 (m, 1H), 3.16 – 3.00 (m, 1H), 2.43 – 2.26 (m, 2H), 0.27 (s, 9H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.2, 151.1, 143.4, 143.2, 139.2, 139.1, 133.9, 133.89, 129.5, 129.4, 126.8, 126.78, 125.7, 125.6, 125.3, 124.9, 121.8, 121.7, 107.9, 107.5, 48.5, 47.9, 38.7, 38.6, 29.4, 29.2, -1.0.


HRMS (ESI): *m/z* calcd for C₂₁H₂₆O₂NSi⁺ [M + H]⁺ 352.1727 found 352.1721.

IR (ν_{max}/cm⁻¹) 1727, 1656, 1495, 1406, 1360, 1249, 1202, 1163, 840, 816, 752, 724, 689.


SFC Conditions: Chiralpak IB; Gradient 1; 95:5 er (major enantiomer *t_R* = 2.98 min; minor enantiomer *t_R* = 2.86 min), **90% ee**. [α]_D²⁵ = -65.5 (c = 2.0, CHCl₃).



Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDALFLR Match1 Spect. Name	PDALFLR Match1 Angle	PDALFLR Match1 Threshold	PDALFLR Match1 Lib. Name	Area (μV*sec)	%Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	2.867							2272025	48.70	1066600	bb			Unknown	
2	2.962							2362993	51.30	876027	bb			Unknown	



Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDALFLR Match1 Spect. Name	PDALFLR Match1 Angle	PDALFLR Match1 Threshold	PDALFLR Match1 Lib. Name	Area (μV*sec)	%Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	2.860							343711	4.90	174233	bb			Unknown	
2	2.978							6662119	95.10	2441225	bb			Unknown	





Phenyl-(S)-3-(4-(trifluoromethyl)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3d): The corresponding compound was prepared following general procedure **A** using 4-(trifluoromethyl)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3d** as viscous liquid (73% yield, 98% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.59 (dt, *J* = 8.8, 4.7 Hz, 2H), 7.44 – 7.29 (m, 4H), 7.23 – 6.99 (m, 4H), 5.25 – 5.11 (m, 1H), 4.27 (ddt, *J* = 12.5, 5.1, 2.5 Hz, 1H), 3.56 – 3.33 (m, 1H), 3.17 (dddd, *J* = 20.2, 10.0, 7.6, 3.8 Hz, 1H), 2.46 – 2.26 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.0, 151.8, 151.2, 151.0, 146.9, 146.7, 129.5, 129.48, 127.8, 127.7, 125.8, 125.8, 125.6, 125.2, 121.8, 121.6, 107.4, 107.0, 48.2, 47.5, 38.6, 38.5, 29.2, 29.1. **¹⁹F NMR** (376 MHz, CDCl₃) (2 rotamers) δ (ppm) –62.4, –62.5.

HRMS (ESI): *m/z* calcd for C₁₉H₁₇F₃O₂N⁺ [M + H]⁺ 348.1206 found 348.1206.

IR (ν_{max}/cm⁻¹) 1725, 1408, 1327, 1202, 1164, 1122, 1068, 1018, 834, 755.

HPLC Conditions: Chiralpak IE; Isocratic 1% IPA/Hexane 1ml/min; 99:1 er (major enantiomer *t_R* = 19.5 min; minor enantiomer *t_R* = 22.1 min), **98% ee**. [α]_D²⁵ = –33.7 (*c* = 2.0, CHCl₃).





Phenyl-(S)-3-(4-methoxyphenyl)-3,4-dihydropyridine-1(2H)-carboxylate (**3e**):



The corresponding compound was prepared following general procedure **A** using 4-methoxyphenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3e** as viscous liquid (52% yield, 98% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.37 (td, *J* = 8.7, 7.2 Hz, 2H), 7.26 – 6.99 (m, 6H), 6.92 – 6.87 (m, 2H), 5.25 – 5.11 (m, 1H), 4.27 (ddd, *J* = 13.7, 6.8, 2.8 Hz, 1H), 3.81 (d, *J* = 1.1 Hz, 4H), 3.49 – 3.25 (m, 1H), 3.12 – 3.01 (m, 1H), 2.43 – 2.24 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 158.7, 158.68, 152.1, 151.8, 151.3, 151.1, 134.9, 134.8, 129.5, 129.4, 128.3, 128.2, 125.7, 125.65, 125.3, 124.9, 121.8, 121.7, 114.3, 114.2, 107.9, 107.5, 55.4, 55.41, 48.8, 48.2, 37.9, 37.8, 29.6, 29.5.

HRMS (ESI): *m/z* calcd for C₁₉H₂₀O₃N⁺ [*M* + *H*]⁺ 310.1438 found 310.1457.

IR (ν_{max}/cm⁻¹) 1723, 1514, 1406, 1360, 1250, 1200, 1074, 1036, 828, 751, 722, 689.

SFC Conditions: Chiralpak IC; Gradient 1; 99:1 er (major enantiomer *t_R* = 4.92 min; minor enantiomer *t_R* = 5.08 min), **98% ee**. [*α*]_D²⁵ = -45.9 (*c* = 2.0, CHCl₃).





Phenyl-(S)-3-(4-(benzyloxy)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3f):



The corresponding compound was prepared following general procedure **A** using 4-(benzyloxy)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3f** as white solid (47% yield, 99% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.48 – 7.29 (m, 7H), 7.27 – 6.91 (m, 8H), 5.25 – 5.10 (m, 1H), 5.07 (s, 3H), 4.41 – 4.24 (m, 1H), 3.46 – 3.24 (m, 1H), 3.12 – 2.96 (m, 1H), 2.43 – 2.24 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 157.9, 152.1, 151.8, 151.3, 151.1, 137.2, 135.2, 135.1, 129.5, 129.4, 128.7, 128.3, 128.27, 128.1, 127.6, 127.56, 125.7, 125.6, 125.3, 124.9, 121.8, 121.7, 115.25, 115.19, 107.9, 107.5, 70.2, 48.8, 48.2, 37.9, 37.8, 29.6, 29.4.

HRMS (ESI): m/z calcd for C₂₅H₂₄O₃N⁺ [M + H]⁺ 386.1751 found 386.1761.

IR (ν_{max}/cm⁻¹) 1721, 1512, 1361, 1250, 1200, 1075, 1024, 827, 749, 691, 690.

SFC Conditions: Chiralpak IE; Gradient 1; 99.5:0.5 er (major enantiomer t_R = 6.97 min; minor enantiomer t_R = 6.78 min), **99% ee**. [α]_D²⁵ = –59.1 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(4-(trifluoromethoxy)phenyl)-3,4-dihydropyridine-1(2H)-


carboxylate (3g): The corresponding compound was prepared following general procedure **A** using 4-(trifluoromethoxy)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3g** as viscous liquid (50% yield, 99% ee).

¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.40 – 7.00 (m, 10H), 5.25 – 5.09 (m, 1H), 4.27 (t, *J* = 10.7 Hz, 1H), 3.56 – 3.28 (m, 1H), 3.13 (ddd, *J* = 15.6, 10.6, 6.0 Hz, 1H), 2.46 – 2.27 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.2, 151.0, 148.3, 141.6, 141.4, 129.54, 129.5, 128.71, 128.7, 125.8, 125.5, 125.1, 121.8, 121.7, 121.5, 121.4, 107.5, 107.1, 48.4, 47.8, 38.1, 38.0, 29.4, 29.3. **¹⁹F NMR** (376 MHz, CDCl₃) (2 rotamers): δ (ppm) –57.88, –57.90.


HRMS (ESI): *m/z* calcd for C₁₉H₁₇O₃NF₃⁺ [M + H]⁺ 364.1155 found 364.1162.

IR (ν_{max}/cm⁻¹) 1724, 1656, 1510, 1407, 1361, 1263, 1198, 1163, 1075, 846, 750, 689.


SFC Conditions: Chiralpak IA; Gradient 3; 93:7 er (major enantiomer *t_R* = 5.35 min; minor enantiomer *t_R* = 5.19 min), **86% ee**. [*α*]_D²⁵ = –39.7 (*c* = 2.0, CHCl₃).



3	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDIAFLR Match1 Spect. Name	PDIAFLR Match1 Angle	PDIAFLR Match1 Threshold	PDIAFLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	5.188							640994	49.17	152008	bb			Unknown	
2	5.355							862750	50.83	139113	bb			Unknown	



3	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDIAFLR Match1 Spect. Name	PDIAFLR Match1 Angle	PDIAFLR Match1 Threshold	PDIAFLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	5.194							82293	6.06	21115	bb			Unknown	
2	5.354							118871	93.14	254466	bb			Unknown	



Phenyl-(S)-3-(4-(methylthio)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate



(3h): The corresponding compound was prepared following general procedure **A** using 4-(methylthio)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3h** as viscous liquid (70% yield, 86% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.34 (dtd, *J* = 8.7, 7.2, 1.9 Hz, 2H), 7.25 – 6.90 (m, 8H), 5.24 – 5.04 (m, 1H), 4.32 – 4.14 (m, 1H), 3.51 – 3.17 (m, 1H), 3.13 – 2.93 (m, 1H), 2.46 (s, 3H), 2.37 – 2.22 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.2, 151.1, 139.7, 139.6, 137.1, 137.0, 129.5, 129.4, 127.83, 127.80, 127.3, 127.2, 125.7, 125.68, 125.3, 124.9, 121.8, 121.7, 107.7, 107.4, 48.5, 47.9, 38.2, 38.0, 29.4, 29.2, 16.2, 16.1.

HRMS (ESI): *m/z* calcd for C₁₉H₂₀O₂SN⁺ [M + H]⁺ 326.1209 found 326.1198.

IR (ν_{max}/cm⁻¹) 1721, 1495, 1406, 1353, 1266, 1200, 1163, 1095, 1074, 973, 817, 748, 690.

SFC Conditions: Chiralpak IB; Gradient 1; 93:7 er (major enantiomer *t_R* = 4.93 min; minor enantiomer *t_R* = 4.52 min), **86% ee**. [α]_D²⁵ = -77.3 (c = 2.0, CHCl₃).






Phenyl-(S)-3-(4-fluorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3i): The corresponding compound was prepared following general procedure **A** using 4-fluorophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 12% acetone/petrol) afforded compound **3i** as viscous liquid (75% yield, 94% ee).

¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.37 (dt, J = 10.8, 8.0 Hz, 2H), 7.25 – 6.98 (m, 8H), 5.25 – 5.09 (m, 1H), 4.26 (ddt, J = 16.4, 12.4, 2.3 Hz, 1H), 3.51 – 3.25 (m, 1H), 3.10 (dtt, J = 15.8, 10.5, 4.5 Hz, 1H), 2.43 – 2.25 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (¹⁹F decoupled) (2 rotamers): δ (ppm) 163.1, 160.7, 152.1, 151.8, 151.2, 151.0, 138.5, 138.4, 129.5, 129.46, 128.8, 128.78, 128.74, 128.70, 125.7, 125.4, 125.0, 121.8, 121.7, 115.8, 115.76, 115.6, 115.5, 107.6, 107.3, 48.6, 48.0, 38.0, 37.9, 29.5, 29.4. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –115.8, –115.9.


HRMS (ESI): m/z calcd for C₁₈H₁₇O₂FN⁺ [M + H]⁺ 298.1238 found 298.1244.

IR (ν_{max}/cm⁻¹) 1724, 1511, 1406, 1361, 1200, 1162, 1074, 832, 753, 730, 689.


SFC Conditions: Chiralpak ID; Gradient 1; 97:3 er (major enantiomer t_R = 3.04 min; minor enantiomer t_R = 2.97 min), **94% ee**. [α]_D²⁵ = –39.3 (c = 2.0, CHCl₃).



Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDA/FLR Match1 Spect Name	PDA/FLR Match1 Angle	PDA/FLR Match1 Threshold	PDA/FLR Match1 Lib. Name	Area (μV*sec)	%Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	2.992							488589	47.07	197622	uv			Unknown	
2	3.001							494491	52.83	197688	uv			Unknown	



Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDA/FLR Match1 Spect Name	PDA/FLR Match1 Angle	PDA/FLR Match1 Threshold	PDA/FLR Match1 Lib. Name	Area (μV*sec)	%Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	2.973							32733	2.86	16252	uv			Unknown	
2	3.043							1086581	97.02	481350	uv			Unknown	





Phenyl-(S)-3-(4-chlorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3j): The corresponding compound was prepared following general procedure **A** using 4-chlorophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3j** as viscous liquid (63% yield, 98% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.42 – 7.28 (m, 4H), 7.26 – 6.99 (m, 6H), 5.26 – 5.10 (m, 1H), 4.32 – 4.20 (m, 1H), 3.52 – 3.24 (m, 1H), 3.09 (qdd, *J* = 10.3, 7.6, 3.7 Hz, 1H), 2.44 – 2.23 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 151.8, 151.2, 151.0, 141.3, 141.2, 132.9, 129.5, 129.48, 129.04, 129.0, 128.7, 128.67, 125.8, 125.5, 125.1, 121.8, 121.7, 107.5, 107.1, 48.4, 47.8, 38.1, 38.0, 29.4, 29.2.

HRMS (ESI): *m/z* calcd for C₁₈H₁₇O₂ClN⁺ [M + H]⁺ 314.0942 found 314.0937.

IR (ν_{max}/cm⁻¹) 1723, 1494, 1405, 1352, 1199, 1074, 821, 749, 689.

SFC Conditions: Chiralpak IA; Gradient 1; 99:1 er (major enantiomer *t_R* = 4.31 min; minor enantiomer *t_R* = 4.17 min), **98% ee**. [α]_D²⁵ = -50.1 (c = 2.0, CHCl₃).







Phenyl-(S)-3-(4-bromophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3k): The corresponding compound was prepared following general procedure **A** using 4-bromophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3k** as white solid (60% yield, 98% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.51 – 7.32 (m, 5H), 7.25 – 7.00 (m, 5H), 5.25 – 5.08 (m, 1H), 4.37 – 4.15 (m, 1H), 3.52 – 3.24 (ddd, *J* = 70.1, 12.6, 11.0 Hz, 1H), 3.16 – 3.01 (m, 1H), 2.53 – 2.13 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.0, 151.8, 151.2, 151.0, 141.8, 141.7, 132.0, 131.9, 129.5, 129.47, 129.1, 129.0, 125.8, 125.5, 125.1, 121.8, 121.7, 107.5, 107.1, 48.3, 47.7, 38.2, 38.1, 29.3, 29.2.

HRMS (ESI): *m/z* calcd for C₁₈H₁₇O₂BrN⁺ [M + H]⁺ 358.0437 found 358.0430.

IR (ν_{max}/cm⁻¹) 1721, 1492, 1405, 1361, 1254, 1199, 1072, 1009, 816, 749, 689, 689.

SFC Conditions: Chiralpak IE; Gradient 1; 99:1 er (major enantiomer *t_R* = 5.34 min; minor enantiomer *t_R* = 5.11 min), **98% ee**. [α]_D²⁵ = -60.1 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(4-(methoxycarbonyl)phenyl)-3,4-dihydropyridine-1(2H)-



carboxylate (3I): The corresponding compound was prepared following general procedure **A** using 4-(methoxycarbonyl)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (5% acetone/petrol to 20% acetone/petrol) afforded compound **3I** as viscous liquid (62% yield, 97% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 8.07 – 7.97 (m, 2H), 7.43 – 7.30 (m, 5H), 7.24 – 7.01 (m, 3H), 5.20 – 5.12 (m, 1H), 4.34 – 4.24 (m, 1H), 3.94 – 3.90 (m, 3H), 3.56 – 3.31 (m, 1H), 3.16 (ddt, *J* = 15.6, 10.0, 4.5 Hz, 1H), 2.45 – 2.29 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 167.0, 152.1, 151.8, 151.2, 151.0, 148.0, 147.9, 130.2, 130.17, 129.5, 129.48, 129.1, 129.06, 127.4, 127.38, 125.8, 125.5, 125.1, 121.8, 121.7, 107.5, 107.1, 52.3, 52.2, 48.1, 47.5, 38.8, 38.6, 29.2, 29.1.

HRMS (ESI): *m/z* calcd for C₂₀H₂₀O₄N⁺ [M + H]⁺ 338.1387 found 338.1386.

IR (ν_{max}/cm⁻¹) 1721, 1406, 1360, 1281, 1200, 1112, 1075, 846, 751, 707, 690.

SFC Conditions: Chiralpak IC; Gradient 1; 98.5:1.5 er (major enantiomer *t_R* = 6.41 min; minor enantiomer *t_R* = 6.58 min), **97% ee**. [α]_D²⁵ = -60.7 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(4-cyanophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3m): The corresponding compound was prepared following general procedure **A** using 4-cyanophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3m** as viscous liquid (37% yield, 96% ee).



¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.64 (dt, *J* = 8.1, 5.7 Hz, 2H), 7.37 (qd, *J* = 8.1, 4.4 Hz, 4H), 7.25 – 7.00 (m, 4H), 5.25 – 5.10 (m, 1H), 4.26 (dddd, *J* = 14.6, 12.6, 3.9, 1.7 Hz, 1H), 3.58 – 3.32 (m, 1H), 3.18 (qdd, *J* = 10.0, 7.5, 4.4 Hz, 1H), 2.50 – 2.25 (m, 2H).


¹³C NMR (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.0, 151.7, 151.1, 150.9, 148.2, 148.1, 132.7, 132.68, 129.53, 129.5, 128.2, 128.18, 125.9, 125.6, 125.2, 121.7, 121.6, 118.8, 107.1, 106.7, 47.8, 47.2, 38.8, 38.6, 29.0, 28.9.

HRMS (ESI): *m/z* calcd for C₁₉H₁₇O₂N₂⁺ [M + H]⁺ 305.1285 found 305.1290.

IR (ν_{max}/cm⁻¹) 2229, 1720, 1408, 1343, 1266, 1200, 1164, 1073, 831, 752, 689.

SFC Conditions: Chiralpak IE; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 6.16 min; minor enantiomer *t_R* = 6.07 min), **96% ee**. [α]_D²⁵ = -75.6 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(4-(1H-pyrazol-1-yl)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3n):



The corresponding compound was prepared following general procedure **A** using 4-(1H-pyrazol-1-yl)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3n** as viscous liquid (58% yield, 96% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.92 (d, *J* = 2.4 Hz, 1H), 7.73 (d, *J* = 2.5 Hz, 1H), 7.68 (dt, *J* = 8.3, 6.2 Hz, 2H), 7.40 – 7.31 (m, 4H), 7.25 – 7.01 (m, 4H), 6.47 (q, *J* = 2.4 Hz, 1H), 5.27 – 5.10 (m, 1H), 4.39 – 4.22 (m, 1H), 3.57 – 3.29 (m, 1H), 3.24 – 3.05 (m, 1H), 2.52 – 2.27 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.2, 151.0, 141.2, 141.0, 140.9, 139.2, 129.5, 129.4, 128.3, 128.28, 126.8, 125.7, 125.4, 125.0, 121.8, 121.7, 119.6, 119.59, 107.7, 107.6, 107.2, 48.4, 47.8, 38.2, 38.0, 29.4, 29.3.

HRMS (ESI): *m/z* calcd for C₂₁H₂₀O₂N₃⁺ [M + H]⁺ 346.1550 found 346.1553.

IR (ν_{max}/cm⁻¹) 1717, 1526, 1396, 1335, 1254, 1200, 1164, 1074, 1047, 937, 833, 751, 690.

SFC Conditions: Chiralpak IF; Gradient 2; 98:2 er (major enantiomer *t_R* = 4.28 min; minor enantiomer *t_R* = 4.66 min), **96% ee**. [α]_D²⁵ = -56.6 (*c* = 2.0, CHCl₃).







Phenyl-(S)-3-(m-tolyl)-3,4-dihydropyridine-1(2H)-carboxylate (3o): The corresponding compound was prepared following general procedure **A** using *m*-tolyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3o** as viscous liquid (70% yield, 96% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.44 – 7.31 (m, 2H), 7.31 – 6.98 (m, 8H), 5.26 – 5.10 (m, 1H), 4.37 – 4.25 (m, 1H), 3.53 – 3.18 (m, 1H), 3.06 (dddd, *J* = 15.2, 10.6, 8.8, 3.7 Hz, 1H), 2.41 – 2.29 (m, 5H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.7, 151.2, 151.1, 142.8, 142.6, 138.5, 138.4, 129.5, 129.4, 128.8, 128.7, 128.1, 127.9, 127.8, 125.7, 125.6, 125.2, 124.9, 124.3, 124.3, 121.8, 121.7, 107.9, 107.5, 48.6, 48.0, 38.7, 38.5, 29.5, 29.4, 21.6.

HRMS (ESI): *m/z* calcd for C₁₉H₂₀O₂N⁺ [M + H]⁺ 294.1489 found 294.1496.

IR (ν_{max}/cm⁻¹) 1724, 1406, 1360, 1203, 1074, 786, 750, 725, 704, 689.

SFC Conditions: Chiralpak IC; Gradient 1; 98:2 er (major enantiomer *t*_R = 4.01 min; minor enantiomer *t*_R = 4.22 min), **96% ee**. [α]²⁵_D = -52.3 (*c* = 2.0, CHCl₃).






Phenyl-(S)-3-(3-(trifluoromethyl)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3p): The corresponding compound was prepared following general procedure **A** using 3-(trifluoromethyl)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3p** as viscous liquid (60% yield, 97% ee).

¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.57 – 7.44 (m, 5H), 7.38 (dt, *J* = 11.3, 8.0 Hz, 2H), 7.26 – 7.02 (m, 4H), 5.28 – 5.11 (m, 1H), 4.36 – 4.25 (m, 1H), 3.59 – 3.30 (m, 1H), 3.19 (dddd, *J* = 20.1, 10.2, 7.7, 3.7 Hz, 1H), 2.48 – 2.31 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.0, 151.8, 151.2, 151.0, 143.7, 143.6, 130.8, 129.5, 129.48, 129.4, 129.3, 125.8, 125.5, 125.2, 124.1, 124.07, 121.8, 121.7, 107.3, 107.0, 48.2, 47.6, 38.6, 38.4, 29.3, 29.2. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –62.5, –62.6.


HRMS (ESI): *m/z* calcd for C₁₉H₁₆O₂F₃N⁺ [*M* + H]⁺ 348.1206 found 348.1210.

IR (ν_{max}/cm⁻¹) 1724, 1408, 1331, 1257, 1202, 1164, 1124, 1074, 803, 752, 703, 689.


SFC Conditions: Chiralpak IA; Gradient 1; 98.5:1.5 er (major enantiomer *t_R* = 2.45 min; minor enantiomer *t_R* = 2.38 min), **97% ee**. [α]_D²⁵ = –39.4 (*c* = 2.0, CHCl₃).



Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PSA/FLR Match1 Spect. Name	PSA/FLR Match1 Angle	PSA/FLR Match1 Threshold	PSA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int. Type	Amount	Units	Peak Type	Peak Codes
1	2.385							400550	50.41	185149	bv			Unknown	
2	2.461							380552	49.59	170639	vb			Unknown	



Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PSA/FLR Match1 Spect. Name	PSA/FLR Match1 Angle	PSA/FLR Match1 Threshold	PSA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int. Type	Amount	Units	Peak Type	Peak Codes
1	2.383							6921	1.54	3830	bb			Unknown	
2	2.450							384722	98.46	159410	bb			Unknown	



Phenyl-(S)-3-(3-(trimethylsilyl)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate



(3q): The corresponding compound was prepared following general procedure **A** using 3-(trimethylsilyl)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 10% acetone/petrol) afforded compound **3q** as viscous liquid (70% yield, 96% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.49 – 7.34 (m, 5H), 7.29 – 7.03 (m, 5H), 5.29 – 5.13 (m, 1H), 4.39 – 4.28 (m, 1H), 3.57 – 3.29 (m, 1H), 3.13 (pd, *J* = 11.8, 3.8 Hz, 1H), 2.46 – 2.31 (m, 2H), 0.34 – 0.28 (m, 9H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.2, 151.1, 142.0, 141.9, 141.3, 141.2, 132.4, 132.4, 132.2, 132.1, 129.5, 128.3, 128.2, 127.7, 127.6, 125.7, 125.6, 125.3, 124.9, 121.8, 121.7, 107.9, 107.6, 48.6, 48.0, 38.9, 38.8, 29.5, 29.49, -1.0.

HRMS (ESI): *m/z* calcd for C₂₁H₂₆O₂NSi⁺ [M + H]⁺ 352.1727 found 352.1734.

IR (ν_{max}/cm⁻¹) 1727, 1656, 1405, 1358, 1249, 1202, 858, 839, 751, 689, 690.

SFC Conditions: Chiralpak IG; Gradient 1; 98:2 er (major enantiomer *t_R* = 3.00 min; minor enantiomer *t_R* = 2.84 min), **96% ee**. [α]_D²⁵ = -22.7 (*c* = 2.0, CHCl₃).





Phenyl-(S)-3-(3-methoxyphenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3r):


The corresponding compound was prepared following general procedure **A** using 3-methoxyphenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3r** as viscous liquid (79% yield, 98% ee).

¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.42 – 7.33 (m, 2H), 7.32 – 6.99 (m, 5H), 6.90 – 6.78 (m, 3H), 5.26 – 5.10 (m, 1H), 4.32 (ddd, *J* = 11.5, 9.7, 3.7 Hz, 1H), 3.85 – 3.72 (m, 3H), 3.53 – 3.26 (m, 1H), 3.08 (qdd, *J* = 10.2, 6.1, 3.8 Hz, 1H), 2.45 – 2.27 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 160.0, 159.96, 152.1, 151.7, 151.2, 151.0, 144.5, 144.3, 129.9, 129.8, 129.5, 129.4, 125.7, 125.6, 125.3, 124.9, 121.8, 121.7, 119.6, 113.5, 113.3, 112.1, 112.08, 107.8, 107.4, 55.32, 55.3, 48.5, 47.9, 38.8, 38.6, 29.4, 29.3.


HRMS (ESI): *m/z* calcd for C₁₉H₂₀O₃N⁺ [M + H]⁺ 310.1438 found 310.1441.

IR (ν_{max}/cm⁻¹) 1723, 1655, 1600, 1494, 1406, 1376, 1360, 1266, 1204, 784, 751.


SFC Conditions: Chiralpak IC; Gradient 1; 99:1 er (major enantiomer *t_R* = 4.65 min; minor enantiomer *t_R* = 4.89 min), **98% ee**. [α]_D²⁵ = -29.8 (c = 2.0, CHCl₃).



Peak Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	FOA/FLR Match1 Spect. Name	FOA/FLR Match1 Angle	FOA/FLR Match1 Threshold	FOA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	4.651							1987215	49.97	535996	bb			Unknown	
2	4.889							1989204	50.03	404262	bb			Unknown	



Peak Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	FOA/FLR Match1 Spect. Name	FOA/FLR Match1 Angle	FOA/FLR Match1 Threshold	FOA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int Type	Amount	Units	Peak Type	Peak Codes
1	4.655							4874488	99.17	1278233	bb			Unknown	
2	4.891							38957	0.83	8584	bb			Unknown	





Phenyl-(S)-3-(3-hydroxyphenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3s): The corresponding compound was prepared following general procedure **A** using 3-hydroxyphenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (5% acetone/petrol to 30% acetone/petrol) afforded compound **3s** as viscous liquid (41% yield, 83% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.36 (dtd, *J* = 9.1, 7.4, 1.9 Hz, 2H), 7.26 – 6.95 (m, 5H), 6.82 (dtd, *J* = 10.5, 7.4, 1.4 Hz, 1H), 6.74 – 6.67 (m, 2H), 5.25 – 5.09 (m, 2H), 4.34 – 4.22 (m, 1H), 3.51 – 3.22 (m, 1H), 3.12 – 2.93 (m, 1H), 2.42 – 2.22 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 156.2, 156.1, 152.3, 151.9, 151.2, 151.0, 144.7, 144.5, 130.05, 130.0, 129.5, 129.49, 125.81, 125.8, 125.2, 124.9, 121.8, 121.7, 119.62, 119.6, 114.30, 114.29, 114.1, 114.06, 108.1, 107.7, 48.5, 47.9, 38.6, 38.4, 29.4, 29.2.

HRMS (ESI): *m/z* calcd for C₁₈H₁₈O₃N⁺ [M + H]⁺ 296.1281 found 296.1280.

IR (ν_{max}/cm⁻¹) 3393, 1699, 1656, 1591, 1494, 1456, 1409, 1361, 1203, 787, 753.

SFC Conditions: Chiralpak IE; Gradient 1; 91.5:8.5 er (major enantiomer *t_R* = 5.35 min; minor enantiomer *t_R* = 5.12 min), **83% ee**. [α]_D²⁵ = -37.3 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(3-(methylthio)phenyl)-3,4-dihydropyridine-1(2H)-carboxylate(3t):


The corresponding compound was prepared following general procedure **A** using 3-(methylthio)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3t** as viscous liquid (70% yield, 99% ee).

¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.42 – 7.33 (m, 2H), 7.31 – 7.00 (m, 8H), 5.25 – 5.09 (m, 1H), 4.35 – 4.25 (m, 1H), 3.52 – 3.26 (m, 1H), 3.53 – 3.25 (m, 1H), 2.51 – 2.47 (m, 3H), 2.43 – 2.26 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.7, 151.2, 151.0, 143.5, 143.4, 139.1, 139.0, 129.5, 129.4, 129.36, 129.3, 125.7, 125.69, 125.64, 125.6, 125.3, 125.2, 125.15, 125.0, 124.1, 121.8, 121.7, 107.7, 107.3, 48.4, 47.8, 38.7, 38.6, 29.4, 29.3, 15.9.


HRMS (ESI): m/z calcd for C₁₉H₂₀O₂SN⁺ [M + H]⁺ 326.1209 found 326.1211.

IR (ν_{max}/cm⁻¹) 1722, 1406, 1359, 1254, 1201, 1074, 786, 748, 690.


SFC Conditions: Chiralpak IC; Gradient 1; 99.5:0.5 er (major enantiomer t_R = 5.11 min; minor enantiomer t_R = 5.30 min), **99% ee**. [α]_D²⁵ = -40.2 (c = 2.0, CHCl₃).



#	Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDA/FLR Match1 Spect. Name	PDA/FLR Match1 Angle	PDA/FLR Match1 Threshold	PDA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int. Type	Amount	Units	Peak Type	Peak Codes
1		5.111							862680	49.29	161511	bb			Unknown	
2		5.301							576990	56.71	138570	bb			Unknown	



#	Name	Retention Time (min)	Purity1 Angle	Purity1 Threshold	PDA/FLR Match1 Spect. Name	PDA/FLR Match1 Angle	PDA/FLR Match1 Threshold	PDA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int. Type	Amount	Units	Peak Type	Peak Codes
1		5.106							1571207	99.54	450363	bb			Unknown	
2		5.299							7253	0.46	2511	bb			Unknown	05





Phenyl-(S)-3-(3-fluorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3u): The corresponding compound was prepared following general procedure **A** using 3-fluorophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3u** as viscous liquid (75% yield, 98% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.42 – 7.29 (m, 3H), 7.25 – 6.93 (m, 7H), 5.18 (dddd, *J* = 37.5, 8.1, 5.2, 2.6 Hz, 1H), 4.30 (ddq, *J* = 14.4, 12.7, 1.6 Hz, 1H), 3.41 (ddd, *J* = 86.7, 12.7, 11.2 Hz, 1H), 3.19 – 3.06 (m, 1H), 2.45 – 2.27 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 163.2, 151.7, 151.2, 151.0, 145.4, 145.3, 130.4, 130.3, 129.5, 129.46, 125.8, 125.4, 125.0, 123.0, 121.8, 121.7, 114.3, 114.2, 114.0, 113.98, 107.5, 107.1, 48.3, 47.7, 38.5, 38.3, 29.3, 29.1. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –112.68, –112.81.

HRMS (ESI): *m/z* calcd for C₁₈H₁₇O₂FN⁺ [M + H]⁺ 298.1238 found 298.1250.

IR (ν_{max}/cm⁻¹) 1723, 1656, 1591, 1407, 1361, 1266, 1203, 1076, 977, 860, 751, 729, 690.

SFC Conditions: Chiralpak IC; Gradient 1; 99:1 er (major enantiomer *t_R* = 3.62 min; minor enantiomer *t_R* = 3.83 min), **98% ee**. [α]_D²⁵ = –45.0 (*c* = 2.0, CHCl₃).







Phenyl-(S)-3-(3-chlorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3v): The corresponding compound was prepared following general procedure **A** using 3-chlorophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3v** as viscous liquid (78% yield, 98% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.38 (td, *J* = 9.1, 7.5 Hz, 2H), 7.31 – 7.19 (m, 4H), 7.18 – 7.01 (m, 4H), 5.25 – 5.09 (m, 1H), 4.29 (dddd, *J* = 14.3, 12.6, 4.3, 1.6 Hz, 1H), 3.53 – 3.26 (m, 1H), 3.09 (dddd, *J* = 20.1, 10.4, 5.8, 2.7 Hz, 1H), 2.47 – 2.23 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.0, 151.7, 151.2, 151.0, 144.8, 144.7, 134.7, 134.6, 130.2, 130.1, 129.5, 129.47, 127.6, 127.5, 127.3, 127.29, 125.8, 125.6, 125.4, 125.1, 121.8, 121.7, 107.4, 107.1, 48.2, 47.6, 38.5, 38.3, 29.3, 29.1.

HRMS (ESI): *m/z* calcd for C₁₈H₁₆O₂ClN⁺ [M + H]⁺ 314.0942 found 314.0953.

IR (ν_{max}/cm⁻¹) 1722, 1406, 1359, 1258, 1201, 1164, 1074, 786, 749, 690.

SFC Conditions: Chiralpak IF; Gradient 1; 99:1 er (major enantiomer *t_R* = 4.81 min; minor enantiomer *t_R* = 5.00 min), **98% ee**. [α]_D²⁵ = -35.3 (*c* = 2.0, CHCl₃).







Phenyl-(S)-3-(3-bromophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3w): The corresponding compound was prepared following general procedure **A** using 3-bromophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3w** as viscous liquid (60% yield, 99% ee).


¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.45 – 7.33 (m, 4H), 7.25 – 7.00 (m, 6H), 5.26 – 5.01 (m, 1H), 4.31 – 4.24 (m, 1H), 3.60 – 3.24 (m, 1H), 3.08 (tp, *J* = 10.4, 5.4 Hz, 1H), 2.46 – 2.25 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.0, 151.7, 151.2, 151.0, 145.1, 145.0, 130.52, 130.5, 130.42, 130.4, 130.31, 130.3, 129.5, 129.48, 129.46, 129.4, 126.0, 125.8, 125.4, 125.1, 123.0, 122.9, 121.8, 121.7, 107.4, 107.1, 48.3, 47.7, 38.5, 38.3, 29.3, 29.2.

HRMS (ESI): *m/z* calcd for C₁₈H₁₇O₂BrN⁺ [M + H]⁺ 358.0437 found 358.0434.

IR (ν_{max}/cm⁻¹) 1723, 1406, 1360, 1257, 1201, 1072, 783, 750, 690.

SFC Conditions: Chiralpak IG; Gradient 1; 99:1 er (major enantiomer *t_R* = 5.80 min; minor enantiomer *t_R* = 6.00 min), **98% ee**. [α]_D²⁵ = -34.5 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(3-(methoxycarbonyl)phenyl)-3,4-dihydropyridine-1(2H)-



carboxylate (3x): The corresponding compound was prepared following general procedure **A** using 3-(methoxycarbonyl)phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3x** as viscous liquid (50% yield, 96% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 8.00 – 7.89 (m, 2H), 7.50 – 7.32 (m, 4H), 7.26 – 7.00 (m, 4H), 5.26 – 5.11 (m, 1H), 4.35 – 4.25 (m, 1H), 3.96 – 3.87 (m, 3H), 3.58 – 3.31 (m, 1H), 3.23 – 3.10 (m, 1H), 2.45 – 2.32 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 167.1, 152.1, 151.8, 151.2, 151.0, 143.2, 143.0, 132.0, 130.8, 130.7, 129.51, 129.5, 129.0, 128.9, 128.5, 128.43, 128.42, 128.40, 125.8, 125.4, 125.1, 121.8, 121.7, 107.6, 107.2, 52.3, 48.3, 47.7, 38.6, 38.4, 29.3, 29.2.

HRMS (ESI): m/z calcd for C₂₀H₂₀O₄N⁺ [M + H]⁺ 338.1387 found 338.1390.

IR (ν_{max}/cm⁻¹) 1721, 1406, 1361, 1290, 1254, 1202, 752, 690.

SFC Conditions: Chiralpak IF; Gradient 1; 98:2 er (major enantiomer t_R = 5.77 min; minor enantiomer t_R = 5.97 min), **96% ee**. [α]_D²⁵ = -44.3 (c = 2.0, CHCl₃).







Phenyl-(S)-3-(2-fluorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3y): The corresponding compound was prepared following general procedure **A** using 2-fluoro phenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3y** as viscous liquid (25% yield, 99% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) ¹H NMR (500 MHz, CDCl₃) δ 7.42 – 7.28 (m, 4H), 7.25 – 6.93 (m, 9H), 5.30 – 5.05 (m, 1H), 4.30 (t, *J* = 12.4 Hz, 1H), 3.60 – 3.24 (m, 1H), 3.12 (dtt, *J* = 15.0, 10.5, 4.6 Hz, 1H), 2.45 – 2.27 (m, 3H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) ¹³C NMR (126 MHz, CDCl₃) δ 163.18, 151.75, 151.18, 151.00, 145.36, 145.26, 130.35, 130.29, 129.50, 129.46, 125.76, 125.40, 125.05, 123.03, 121.77, 121.67, 114.29, 114.22, 114.03, 113.98, 107.46, 107.09, 48.28, 47.67, 38.45, 38.33, 29.29, 29.15. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –112.7, –112.8.

HRMS (ESI): *m/z* calcd for C₂₀H₂₀O₄N⁺ [M + H]⁺ 338.1387 found 338.1390.

IR (ν_{max}/cm⁻¹) 1723, 1493, 1407, 1363, 1257, 1204, 755, 689.

SFC Conditions: Chiralpak IF; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 3.57 min; minor enantiomer *t_R* = 3.71 min), **99% ee**. [α]²⁵_D = –46.2 (c = 2.0, CHCl₃).






Phenyl-(S)-3-(naphthalen-2-yl)-3,4-dihydropyridine-1(2H)-carboxylate (3z): The corresponding compound was prepared following general procedure **A** using naphthalen-2-yl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3z** as viscous liquid (79% yield, 96% ee).

¹H NMR (400 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.90 – 7.64 (m, 4H), 7.54 – 7.44 (m, 2H), 7.44 – 7.33 (m, 3H), 7.29 – 7.03 (m, 4H), 5.32 – 5.15 (m, 1H), 4.41 (ddd, *J* = 12.1, 7.5, 3.7 Hz, 1H), 3.67 – 3.39 (m, 1H), 3.29 (ttt, *J* = 11.3, 7.5, 3.7 Hz, 1H), 2.48 (ddd, *J* = 8.5, 3.7, 2.0 Hz, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.2, 151.1, 140.2, 140.1, 133.7, 132.6, 129.5, 129.4, 128.6, 128.5, 127.8, 127.8, 127.76, 126.4, 126.3, 125.9, 125.85, 125.83, 125.81, 125.7, 125.68, 125.6, 125.4, 125.0, 121.8, 121.7, 107.9, 107.5, 48.5, 47.9, 38.8, 38.7, 29.4, 29.3.


HRMS (ESI): *m/z* calcd for C₂₂H₂₀O₂N⁺ [M + H]⁺ 330.1489 found 330.1493.

IR (ν_{max}/cm⁻¹) 1721, 1406, 1368, 1351, 1202, 1075, 975, 854, 818, 748, 720, 689.


SFC Conditions: Chiralpak IE; Gradient 1; 98:2 er (major enantiomer *t_R* = 6.12 min; minor enantiomer *t_R* = 6.00 min), **96% ee**. [α]_D²⁵ = -89.3 (c = 2.0, CHCl₃).



Peak	Retention Time (min)	Purity1 Angle	Purity1 Threshold	FDA/FLR Match1 Spect. Name	FDA/FLR Match1 Angle	FDA/FLR Match1 Threshold	FDA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int. Type	Amount	Units	Peak Type	Peak Codes
1	5.997						9839939	49.91	2499721	bv				Unknown	
2	6.110						9870501	50.09	2430919	vb				Unknown	



Peak	Retention Time (min)	Purity1 Angle	Purity1 Threshold	FDA/FLR Match1 Spect. Name	FDA/FLR Match1 Angle	FDA/FLR Match1 Threshold	FDA/FLR Match1 Lib. Name	Area (μV*sec)	% Area	Height (μV)	Int. Type	Amount	Units	Peak Type	Peak Codes
1	6.011						97930	1.91	45582	bb				Unknown	
2	6.119						5016185	50.09	1652353	bb				Unknown	



Phenyl-(S)-3-(naphthalen-1-yl)-3,4-dihydropyridine-1(2H)-carboxylate (3aa):



The corresponding compound was prepared following general procedure **A** using naphthalen-1-yl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3aa** as viscous liquid (41% yield, 99% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 8.18 (dd, *J* = 16.9, 8.5 Hz, 1H), 7.91 (t, *J* = 8.2 Hz, 1H), 7.83 – 7.77 (m, 1H), 7.63 – 7.46 (m, 3H), 7.38 (dq, *J* = 16.2, 8.2 Hz, 3H), 7.26 – 7.14 (m, 3H), 7.10 (t, *J* = 7.4 Hz, 1H), 5.38 – 5.15 (m, 1H), 4.50 (t, *J* = 9.1 Hz, 1H), 3.96 (ddt, *J* = 16.1, 9.9, 5.9 Hz, 1H), 3.74 – 3.39 (m, 1H), 2.60 – 2.44 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.7, 151.2, 151.1, 138.7, 138.6, 134.1, 134.0, 131.5, 131.48, 129.5, 129.4, 129.3, 129.2, 127.6, 127.6, 126.5, 126.46, 125.8, 125.79, 125.7, 125.67, 125.4, 125.0, 123.2, 123.1, 122.9, 122.8, 121.8, 121.7, 108.3, 107.8, 48.4, 47.8, 33.5, 33.4, 29.6, 29.4.

HRMS (ESI): *m/z* calcd for C₂₂H₂₀O₂N⁺ [M + H]⁺ 330.1489 found 330.1487.

IR (ν_{max}/cm⁻¹) 1723, 1406, 1369, 1260, 1235, 1204, 798, 749, 689.

SFC Conditions: Chiralpak ID; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 4.51 min; minor enantiomer *t_R* = 4.22 min), **99% ee**. [α]_D²⁵ = -100.1 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(3,5-difluorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (3ab):



The corresponding compound was prepared following general procedure **A** using 3,5-difluorophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3ab** as viscous liquid (70% yield, 94% ee).


¹H NMR (500 MHz, CDCl₃) (2 rotamers): δ (ppm) 7.37 (q, *J* = 8.0 Hz, 2H), 7.26 – 6.99 (m, 4H), 6.85 – 6.65 (m, 3H), 5.26 – 5.08 (m, 1H), 4.33 – 4.21 (m, 1H), 3.55 – 3.24 (m, 1H), 3.11 (ddt, *J* = 14.5, 9.5, 5.1 Hz, 1H), 2.46 – 2.20 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (¹⁹F decoupled) (2 rotamers): δ (ppm) 163.4, 163.3, 152.0, 151.7, 151.1, 150.9, 146.7, 146.6, 129.53, 129.5, 125.8, 125.5, 125.2, 121.8, 121.7, 110.3, 110.27, 107.1, 106.7, 102.6, 102.58, 48.0, 47.4, 38.5, 38.3, 29.1, 29.0. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –109.4, –109.5.

HRMS (ESI): *m/z* calcd for C₁₈H₁₅O₂F₂N⁺ [M + H]⁺ 338.0963 found 338.0976.

IR (ν_{max}/cm⁻¹) 1722, 1625, 1598, 1408, 1379, 1345, 1204, 1118, 982, 851, 750, 690.

SFC Conditions: Chiralpak IC; Gradient 1; 97:3 er (major enantiomer *t_R* = 3.26 min; minor enantiomer *t_R* = 3.40 min), **94% ee**. [α]_D²⁵ = –51.2 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(3-fluoro-4-methylphenyl)-3,4-dihydropyridine-1(2H)-carboxylate



(3ac): The corresponding compound was prepared following general procedure **A** using 3-fluoro-4-methylphenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3ac** as viscous liquid (50% yield, 99% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.37 (q, *J* = 8.1 Hz, 2H), 7.24 – 6.95 (m, 7H), 5.25 – 5.09 (m, 1H), 4.32 – 4.20 (m, 1H), 3.49 – 3.19 (m, 1H), 3.05 (tp, *J* = 10.8, 5.5 Hz, 1H), 2.37 – 2.23 (m, 5H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 160.4, 152.1, 151.8, 151.2, 151.0, 138.2, 138.1, 130.3, 129.5, 129.46, 126.0, 125.9, 125.74, 125.7, 125.3, 125.2, 125.1, 124.9, 121.8, 121.7, 115.3, 115.2, 107.7, 107.4, 48.7, 48.1, 38.0, 37.9, 29.6, 29.5, 14.8. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –120.09, –120.24.

HRMS (ESI): *m/z* calcd for C₁₈H₁₅O₂F₂N⁺ [M + H]⁺ 316.1144 found 316.1168.

IR (ν_{max}/cm⁻¹) 1723, 1504, 1406, 1359, 1251, 1202, 866, 819, 750, 721, 689.

SFC Conditions: Chiralpak IA; Gradient 3; 99.5:0.5 er (major enantiomer *t_R* = 6.30 min; minor enantiomer *t_R* = 6.16 min), **99% ee**. [α]_D²⁵ = –50.8 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(3,4-dichlorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate (**3ad**):



The corresponding compound was prepared following general procedure **A** using 3,4-dichlorophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded compound **3ad** as viscous liquid (60% yield, 96% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.46 – 7.32 (m, 4H), 7.25 – 6.99 (m, 5H), 5.23 – 5.10 (m, 1H), 4.32 – 4.19 (m, 1H), 3.55 – 3.27 (m, 1H), 3.07 (dp, *J* = 14.0, 4.9 Hz, 1H), 2.47 – 2.21 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 151.9, 151.7, 151.1, 150.9, 143.0, 142.9, 132.9, 132.8, 131.1, 131.05, 130.8, 130.7, 129.5, 129.46, 129.4, 129.3, 126.8, 125.8, 125.5, 125.1, 121.7, 121.6, 107.1, 106.8, 48.1, 47.4, 37.9, 37.8, 29.1, 29.0.

HRMS (ESI): *m/z* calcd for C₂₂H₂₀O₂N⁺ [M + H]⁺ 348.0553 found 348.0561.

IR (ν_{max}/cm⁻¹) 1724, 1407, 1374, 1357, 1255, 1202, 749, 689.

SFC Conditions: Chiralpak ID; Gradient 1; 98:2 er (major enantiomer *t_R* = 4.14 min; minor enantiomer *t_R* = 4.28 min), **96% ee**. [α]_D²⁵ = -50.9 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(3-chloro-4-fluorophenyl)-3,4-dihydropyridine-1(2H)-carboxylate



(3ae): The corresponding compound was prepared following general procedure **A** using 3-chloro-4-fluorophenyl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3ae** as viscous liquid (50% yield, 97% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.42 – 7.27 (m, 2H), 7.25 – 6.99 (m, 7H), 5.24 – 5.09 (m, 1H), 4.32 – 4.19 (m, 1H), 3.52 – 3.23 (m, 1H), 3.08 (qt, *J* = 10.6, 5.2 Hz, 1H), 2.44 – 2.22 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 158.44, 155.97, 152.00, 151.74, 151.14, 150.95, 139.84, 139.81, 139.74, 139.70, 129.52, 129.49, 129.47, 129.41, 127.05, 126.98, 125.80, 125.47, 125.13, 121.75, 121.66, 116.98, 116.78, 107.23, 106.89, 48.30, 47.69, 37.82, 37.70, 29.32, 29.22. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –117.9, –118.0.

HRMS (ESI): *m/z* calcd for C₁₈H₁₆O₂FCIN⁺ [M + H]⁺ 332.0848 found 332.0851.

IR (ν_{max}/cm⁻¹) 1724, 1502, 1407, 1376, 1258, 1202, 860, 821, 751, 690.

SFC Conditions: Chiralpak ID; Gradient 1; 98.5:1.5 er (major enantiomer *t_R* = 3.39 min; minor enantiomer *t_R* = 3.48 min), **97% ee**. [α]_D²⁵ = –46.8 (c = 2.0, CHCl₃).







Phenyl-(S)-3-(1H-indol-6-yl)-3,4-dihydropyridine-1(2H)-carboxylate (3af): The corresponding compound was prepared following general procedure **A** using 1H-indol-6-yl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3af** as viscous liquid (35% yield, 86% ee).


¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 8.22 (s, 1H), 7.63 (t, *J* = 7.8 Hz, 1H), 7.45 – 7.30 (m, 2H), 7.30 – 7.13 (m, 5H), 7.15 – 6.99 (m, 2H), 6.53 (s, 1H), 5.31 – 5.11 (m, 1H), 4.38 (dd, *J* = 12.5, 2.9 Hz, 1H), 3.60 – 3.31 (m, 1H), 3.21 (ddt, *J* = 17.6, 11.7, 6.0 Hz, 1H), 2.48 – 2.39 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.3, 151.9, 151.3, 151.1, 136.7, 136.6, 136.22, 136.2, 129.5, 129.4, 127.05, 126.0, 125.7, 125.6, 125.2, 124.8, 124.6, 124.5, 121.8, 121.7, 121.03, 121.0, 119.6, 119.57, 109.51, 109.5, 108.3, 107.9, 102.51, 102.5, 49.1, 48.5, 39.0, 38.8, 30.0, 29.8.

HRMS (ESI): *m/z* calcd for C₂₀H₁₉O₂N₂⁺ [M + H]⁺ 319.1441 found 319.1435.

IR (ν_{max}/cm⁻¹) 3354, 1706, 1407, 1352, 1203, 1074, 873, 811, 753, 731, 689.

SFC Conditions: Chiralpak IB; Gradient 1; 93:7 er (major enantiomer *t_R* = 6.42 min; minor enantiomer *t_R* = 6.22 min), **86% ee**. [α]_D²⁵ = -76.8 (*c* = 2.0, CHCl₃).





Phenyl-(S)-3-(1-methyl-1H-indol-5-yl)-3,4-dihydropyridine-1(2H)-carboxylate



(3ag): The corresponding compound was prepared following general procedure **A** using 1-methyl-1H-indol-5-yl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3ag** as viscous liquid (43% yield, 98% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.64 – 7.52 (m, 1H), 7.47 – 7.30 (m, 3H), 7.30 – 7.04 (m, 6H), 6.51 (t, *J* = 3.0 Hz, 1H), 5.35 – 5.16 (m, 1H), 4.42 (td, *J* = 12.9, 3.6 Hz, 1H), 3.82 – 3.71 (m, 3H), 3.64 – 3.34 (m, 1H), 3.24 (ddt, *J* = 15.6, 11.6, 5.7 Hz, 1H), 2.47 (dt, *J* = 9.2, 3.0 Hz, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 156.1, 152.2, 151.8, 151.3, 151.1, 136.0, 135.97, 133.7, 133.6, 129.4, 129.38, 125.64, 125.6, 125.1, 124.8, 121.8, 121.7, 121.2, 121.15, 119.05, 119.0, 115.4, 109.6, 109.5, 108.4, 108.0, 100.8, 49.3, 48.7, 38.8, 38.6, 32.9, 30.1, 30.0.

HRMS (ESI): *m/z* calcd for C₂₁H₂₀O₂N₂⁺ [M + H]⁺ 333.1598 found 333.1603.

IR (ν_{max}/cm⁻¹) 1720, 1494, 1406, 1348, 1304, 1247, 1203, 1074, 750, 722, 690.

SFC Conditions: Chiralpak IB; Gradient 2; 99:1 er (major enantiomer *t_R* = 3.56 min; minor enantiomer *t_R* = 3.11 min), **98% ee**. [α]_D²⁵ = -68.2 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(1-methyl-1H-indazol-6-yl)-3,4-dihydropyridine-1(2H)-carboxylate



(3ah): The corresponding compound was prepared following general procedure **A** using 1-methyl-1H-indazol-6-yl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3ah** as viscous liquid (81% yield, 99% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.96 (d, *J* = 2.2 Hz, 1H), 7.75 – 7.65 (m, 1H), 7.44 – 7.30 (m, 1H), 7.35 – 7.01 (m, 6H), 5.32 – 5.12 (m, 1H), 4.38 (dt, *J* = 12.3, 4.6 Hz, 1H), 3.68 – 3.34 (m, 1H), 3.27 (pd, *J* = 11.1, 3.6 Hz, 1H), 2.52 – 2.40 (m, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.1, 151.8, 151.2, 151.0, 141.4, 141.3, 140.3, 132.7, 129.51, 129.5, 125.8, 125.7, 125.4, 125.0, 123.32, 123.3, 121.8, 121.6, 121.5, 121.48, 120.6, 107.8, 107.4, 107.1, 107.0, 48.7, 48.1, 39.2, 39.1, 35.6, 29.8, 29.6.

HRMS (ESI): *m/z* calcd for C₂₀H₂₀O₂N₃⁺ [M + H]⁺ 334.1550 found 334.1577.

IR (ν_{max}/cm⁻¹) 1721, 1406, 1367, 1350, 1201, 1098, 973, 839, 750.

SFC Conditions: Chiralpak ID; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 5.86 min; minor enantiomer *t_R* = 5.56 min), **99% ee**. [α]_D²⁵ = -63.8 (c = 2.0, CHCl₃).







Phenyl-(S)-2'-fluoro-3,4-dihydro-[3,4'-bipyridine]-1(2H)-carboxylate (3ai): The corresponding compound was prepared following general procedure **A** using (6-fluoropyridin-4-yl) boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3ai** as viscous liquid (61% yield, 92% ee).


¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 8.19 (t, *J* = 5.7 Hz, 1H), 7.37 (q, *J* = 7.9 Hz, 2H), 7.22 (q, *J* = 7.2 Hz, 1H), 7.16 – 6.96 (m, 4H), 6.83 (d, *J* = 10.4 Hz, 1H), 5.27 – 5.04 (m, 1H), 4.36 – 4.13 (m, 1H), 3.65 – 3.30 (m, 1H), 3.18 (ddp, *J* = 14.6, 9.6, 5.0 Hz, 1H), 2.44 (dt, *J* = 17.5, 5.2 Hz, 1H), 2.37 – 2.27 (m, 1H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 165.3, 163.32, 157.5, 157.4, 151.9, 151.7, 151.0, 150.8, 148.1, 148.0, 129.5, 125.9, 125.7, 125.4, 121.7, 121.6, 120.4, 108.3, 108.1, 106.7, 106.3, 47.3, 46.6, 37.9, 37.7, 28.4, 28.3. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –67.6, –67.8.

HRMS (ESI): *m/z* calcd for C₁₇H₁₆O₂N₂⁺ [M + H]⁺ 299.1190 found 299.1194.

IR (ν_{max}/cm⁻¹) 1722, 1656, 1613, 1567, 1409, 1363, 1257, 1203, 1163, 1077, 751, 690.

SFC Conditions: Chiralpak IC; Gradient 1; 96:4 er (major enantiomer *t_R* = 6.22 min; minor enantiomer *t_R* = 6.46 min), **92% ee**. [α]_D²⁵ = –49.4 (*c* = 2.0, CHCl₃).







Phenyl-(S)-6'-fluoro-3,4-dihydro-[3,3'-bipyridine]-1(2H)-carboxylate (3aj): The corresponding compound was prepared following general procedure **A** using (6-fluoropyridin-3-yl) boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3ai** as viscous liquid (38% yield, 96% ee).


¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 8.15 (d, *J* = 11.9 Hz, 1H), 7.67 (qd, *J* = 9.4, 2.4 Hz, 1H), 7.37 (q, *J* = 8.6 Hz, 2H), 7.23 (t, *J* = 7.5 Hz, 1H), 7.17 – 7.01 (m, 3H), 6.94 (dt, *J* = 8.3, 3.9 Hz, 1H), 5.27 – 5.08 (m, 1H), 4.24 (t, *J* = 14.2 Hz, 1H), 3.69 – 3.32 (m, 1H), 3.18 (ddq, *J* = 15.3, 9.9, 4.8 Hz, 1H), 2.43 (dt, *J* = 17.5, 5.2 Hz, 1H), 2.31 (ddt, *J* = 17.5, 9.9, 2.5 Hz, 1H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 151.8, 151.1, 150.9, 146.7, 146.6, 139.9, 139.87, 135.9, 135.7, 129.6, 129.5, 125.9, 125.7, 125.3, 121.7, 121.6, 109.8, 107.0, 106.6, 48.1, 47.5, 35.4, 29.2. **¹⁹F NMR** (471 MHz, CDCl₃) (2 rotamers): δ (ppm) –70.2, –70.4.

HRMS (ESI): *m/z* calcd for C₁₇H₁₆O₂N₂⁺ [M + H]⁺ 299.1190 found 299.1244.

IR (ν_{max}/cm⁻¹) 1727, 1657, 1598, 1489, 1409, 1376, 1255, 1205, 1078, 855, 751, 751, 690.

SFC Conditions: Chiralpak IB; Gradient 1; 98:2 er (major enantiomer *t_R* = 4.22 min; minor enantiomer *t_R* = 3.97 min), **96% ee**. [α]_D²⁵ = –46.3 (c = 2.0, CHCl₃).





Phenyl-(S)-3-(cyclohex-1-en-1-yl)-3,4-dihydropyridine-1(2H)-carboxylate (3ak):



The corresponding compound was prepared following general procedure **A** using cyclohex-1-en-1-yl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (100% petrol to 5% acetone/petrol) afforded compound **3ak** as viscous liquid (77% yield, 99% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.37 (tt, *J* = 7.6, 2.2 Hz, 2H), 7.25 – 7.19 (m, 1H), 7.16 – 7.11 (m, 1H), 7.02 – 6.86 (m, 1H), 5.56 – 5.46 (m, 1H), 5.16 – 5.00 (m, 1H), 4.23 – 4.10 (m, 1H), 3.35 – 2.96 (m, 1H), 2.34 (ddd, *J* = 15.1, 8.8, 3.5 Hz, 1H), 2.24 – 1.85 (m, 6H), 1.72 – 1.52 (m, 4H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.2, 151.8, 151.3, 151.2, 138.1, 138.0, 129.4, 125.6, 125.0, 124.6, 122.0, 121.9, 121.8, 108.0, 107.7, 47.0, 46.5, 39.64, 39.6, 29.8, 27.3, 27.1, 27.0, 25.3, 23.1, 22.6.

HRMS (ESI): *m/z* calcd for C₁₈H₂₁O₂NNa⁺ [M + Na]⁺ 306.1465 found 306.1468.

IR (ν_{max}/cm⁻¹) 1726, 1656, 1407, 1361, 1252, 1205, 750, 689.

SFC Conditions: Chiralpak IF; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 3.94 min; minor enantiomer *t_R* = 4.16 min), **99% ee**. [α]_D²⁵ = -48.8 (c = 2.0, CHCl₃).





Phenyl-(S,E)-3-(pent-1-en-1-yl)-3,4-dihydropyridine-1(2H)-carboxylate (3a1):



The corresponding compound was prepared following general procedure **A** using pent-1-en-1-yl boronic acid and phenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (100% petrol to 5% acetone/petrol) afforded compound **3a1** as viscous liquid (62% yield, 99% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.37 (t, *J* = 8.0 Hz, 2H), 7.22 (t, *J* = 7.4 Hz, 1H), 7.13 (d, *J* = 8.0 Hz, 2H), 7.02 – 6.85 (m, 1H), 5.65 – 5.51 (m, 1H), 5.39 (dt, *J* = 15.3, 7.4 Hz, 1H), 5.11 – 4.96 (m, 1H), 4.05 (td, *J* = 14.4, 2.8 Hz, 1H), 3.38 – 3.02 (m, 1H), 2.64 – 2.42 (m, 1H), 2.20 (dt, *J* = 17.5, 5.0 Hz, 1H), 2.06 – 1.90 (m, 3H), 1.50 – 1.31 (m, 2H), 0.90 (td, *J* = 7.4, 3.5 Hz, 3H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.3, 151.9, 151.3, 151.1, 131.64, 131.6, 130.9, 130.8, 129.5, 125.6, 125.1, 124.8, 121.8, 121.78, 107.2, 106.9, 47.8, 47.2, 35.3, 35.2, 34.8, 29.8, 28.3, 28.2, 22.6, 13.7.

HRMS (ESI): *m/z* calcd for C₁₇H₂₁O₂NNa⁺ [*M* + Na]⁺ 294.1465 found 294.1471s.

IR (ν_{max}/cm⁻¹) 1728, 1408, 1364, 1204, 972, 750, 689.

SFC Conditions: Chiralpak IA; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 2.36 min; minor enantiomer *t_R* = 2.25 min), **99% ee**. [*α*]_D²⁵ = -34.2 (*c* = 2.0, CHCl₃).





4-Methoxyphenyl-(S)-3-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (3am):



The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and 4-methoxyphenyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3am** as viscous liquid (85% yield, 98% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.36 – 7.16 (m, 5H), 7.10 – 6.92 (m, 3H), 6.90 – 6.78 (m, 2H), 5.21 – 5.05 (m, 1H), 4.31 – 4.20 (m, 1H), 3.77 – 3.70 (m, 3H), 3.50 – 3.17 (m, 1H), 3.05 (ddq, *J* = 14.3, 7.4, 3.7 Hz, 1H), 2.40 – 2.23 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 157.2, 152.5, 152.1, 144.7, 144.6, 142.8, 142.7, 128.9, 128.8, 127.3, 127.1, 127.06, 125.3, 125.0, 122.6, 122.5, 114.51, 114.5, 107.7, 107.3, 55.7, 48.5, 48.0, 38.7, 38.6, 29.5, 29.3.

HRMS (ESI): *m/z* calcd for C₁₉H₁₉O₃NNa⁺ [M + Na]⁺ 332.1257 found 332.1257.

IR (ν_{max}/cm⁻¹) 1721, 1508, 1406, 1362, 1249, 1198, 1070, 1034, 974, 862, 817, 757, 701.

SFC Conditions: Chiralpak IB; Gradient 1; 99:1 er (major enantiomer *t_R* = 4.10 min; minor enantiomer *t_R* = 3.94 min), **98% ee**. [α]_D²⁵ = -46.8 (*c* = 2.0, CHCl₃).







Methyl-(S)-3-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (3an): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and methyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3an** as viscous liquid (72% yield, 99% ee).


¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 7.43 – 7.16 (m, 5H), 7.07 – 6.80 (m, 1H), 5.23 – 4.95 (m, 1H), 4.34 – 4.03 (m, 1H), 3.86 – 3.72 (m, 3H), 3.32 – 3.20 (m, 1H), 3.01 (ddt, *J* = 15.2, 6.3, 3.8 Hz, 1H), 2.32 (dt, *J* = 9.8, 2.5 Hz, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) δ 154.1, 153.8, 143.1, 142.9, 128.8, 127.3, 127.0, 125.4, 125.0, 106.4, 106.2, 53.1, 48.0, 47.7, 38.7, 38.6, 29.4, 29.3.

HRMS (ESI): *m/z* calcd for C₁₃H₁₅O₂N⁺ [M + H]⁺ 218.1176 found 218.1181.

IR (ν_{max}/cm⁻¹) 1704, 1447, 1405, 1355, 1268, 1204, 1121, 1052, 980, 762, 701.

SFC Conditions: Chiralpak IC; Gradient 1; 99.5:0.5 er (major enantiomer *t*_R = 2.82 min; minor enantiomer *t*_R = 2.92 min), **99% ee**. [α]_D²⁵ = -30.7 (c = 2.0, CHCl₃).







Isopropyl-(S)-3-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (3ao): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and isopropyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3ao** as viscous liquid (86% yield, 97% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.40 – 7.13 (m, 5H), 7.04 – 6.82 (m, 1H), 5.14 – 5.04 (m, 2H), 4.30 – 4.00 (m, 1H), 3.22 (dt, *J* = 23.4, 12.0 Hz, 1H), 2.99 (tdd, *J* = 10.4, 6.5, 3.7 Hz, 1H), 2.38 – 2.20 (m, 2H), 1.37 – 1.18 (m, 6H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 153.3, 153.0, 143.3, 143.1, 128.8, 128.7, 127.4, 127.3, 127.0, 126.9, 125.5, 125.2, 106.0, 105.7, 69.5, 47.9, 47.5, 38.8, 38.7, 29.6, 22.3.

HRMS (ESI): *m/z* calcd for C₁₅H₂₀O₂N⁺ [M + H]⁺ 246.1489 found 246.1493.

IR (ν_{max}/cm⁻¹) 1702, 1413, 1385, 1320, 1266, 1180, 1110, 924, 759, 701.

SFC Conditions: Chiralpak IC; Gradient 1; 98.5:1.5 er (major enantiomer *t_R* = 2.41 min; minor enantiomer *t_R* = 2.58 min), **97% ee**. [α]_D²⁵ = -27.0 (c = 2.0, CHCl₃).







Benzyl-(S)-3-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (3ap): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and benzyl pyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3ap** as viscous liquid (68% yield, 99% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.46 – 7.19 (m, 10H), 7.09 – 6.89 (m, 1H), 5.29 – 4.97 (m, 3H), 4.34 – 4.08 (m, 1H), 3.31 (dt, *J* = 23.9, 11.8 Hz, 1H), 3.10 – 2.97 (m, 1H), 2.33 (d, *J* = 7.2 Hz, 2H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 153.6, 153.2, 143.1, 142.9, 136.4, 128.8, 128.7, 128.4, 128.3, 128.2, 127.4, 127.3, 127.1, 127.0, 125.5, 125.0, 106.7, 106.4, 67.8, 67.7, 48.0, 47.8, 38.7, 38.6, 29.5.

HRMS (ESI): *m/z* calcd for C₁₉H₂₀O₂N⁺ [M + H]⁺ 294.1489 found 294.1488.

IR (ν_{max}/cm⁻¹) 1704, 1411, 1342, 1265, 1115, 757, 699.

SFC Conditions: Chiralpak IF; Gradient 1; 99.5:0.5 er (major enantiomer *t_R* = 3.81 min; minor enantiomer *t_R* = 4.02 min), **99% ee**. [α]_D²⁵ = -23.5 (c = 2.0, CHCl₃).







Phenyl-(S)-6-methyl-3-phenyl-3,4-dihydropyridine-1(2H)-carboxylate (3aq): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and phenyl 6-methylpyridine-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3aq** as viscous liquid (57% yield, 91% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.39 – 7.24 (m, 8H), 7.22 – 7.14 (m, 1H), 6.94 (d, *J* = 7.8 Hz, 1H), 5.23 – 5.16 (m, 1H), 4.19 (dd, *J* = 12.5, 3.0 Hz, 1H), 3.66 – 3.54 (m, 1H), 3.19 (qd, *J* = 8.4, 3.2 Hz, 1H), 2.51 (dddd, *J* = 18.3, 6.1, 4.0, 2.0 Hz, 1H), 2.41 – 2.28 (m, 1H), 2.24 (q, *J* = 2.0 Hz, 3H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 152.8, 151.1, 143.3, 135.8, 129.3, 128.8, 127.3, 126.9, 125.5, 121.8, 112.8, 50.8, 39.7, 30.6, 22.0.

HRMS (ESI): *m/z* calcd for C₁₉H₁₉O₂NNa⁺ [*M* + Na]⁺ 316.1308 found 316.1308.

IR (ν_{max}/cm⁻¹) 1722, 1493, 1385, 1204, 752, 702, 755, 701.

SFC Conditions: Chiralpak IC; Gradient 1; 95.5:4.5 er (major enantiomer *t_R* = 3.86 min; minor enantiomer *t_R* = 3.53 min), **91% ee**. [*α*]_D²⁵ = -40.7 (*c* = 2.0, CHCl₃).







Phenyl-(S)-3-phenyl-3,4-dihydroquinoline-1(2H)-carboxylate (3as): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and phenyl quinoline-1(2H)-carboxylate. The mixture was stirred at 30 °C for 48 hours. Purification by flash chromatography (2% acetone/petrol to 15% acetone/petrol) afforded compound **3as** as viscous liquid (85% yield, 90% ee).


¹H NMR (CDCl₃, 400 MHz) (2 rotamers): δ (ppm) 7.87 (d, *J* = 7.7 Hz, 1H), 7.41 – 7.28 (m, 7H), 7.22 (ddd, *J* = 9.0, 6.5, 4.5 Hz, 3H), 7.15 – 7.03 (m, 3H), 4.36 (ddd, *J* = 12.7, 4.1, 1.2 Hz, 1H), 3.89 – 3.79 (m, 1H), 3.33 (tt, *J* = 9.6, 4.9 Hz, 1H), 3.23 (dd, *J* = 16.4, 5.7 Hz, 1H), 3.12 (dd, *J* = 16.4, 9.6 Hz, 1H). **¹³C NMR** (101 MHz, CDCl₃) (2 rotamers): δ (ppm) 153.3, 151.2, 142.6, 137.8, 129.4, 129.0, 128.9, 127.4, 127.2, 126.4, 125.6, 124.4, 124.1, 121.8, 51.1, 40.3, 34.7.

HRMS (ESI): *m/z* calcd for C₂₂H₂₀O₂N⁺ [M + H]⁺ 330.1489 found 330.1491.

IR (ν_{max}/cm⁻¹) 1722, 1492, 1380, 1197, 1130, 755, 701.

SFC Conditions: Chiralpak IC; Gradient 1; 95:5 er (major enantiomer *t_R* = 5.11 min; minor enantiomer *t_R* = 4.74 min), **90% ee**. [α]_D²⁵ = -7.9 (c = 2.0, CHCl₃).







Phenyl-(S)-6-methyl-3-phenyl-3,4-dihydroquinoline-1(2H)-carboxylate (3at): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and phenyl 6-methylquinoline-1(2H)-carboxylate. The mixture was stirred at 30 °C for 48 hours. Purification by flash chromatography (5% acetone/petrol to 25% acetone/petrol) afforded compound **3at** as viscous liquid (87% yield, 85% ee).


¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 7.71 (s, 1H), 7.39 – 7.32 (m, 4H), 7.32 – 7.27 (m, 2H), 7.23 – 7.18 (m, 1H), 7.09 (d, *J* = 7.8 Hz, 1H), 7.03 (d, *J* = 7.8 Hz, 2H), 6.93 (dd, *J* = 7.8, 1.7 Hz, 1H), 4.32 (ddd, *J* = 12.8, 4.1, 1.2 Hz, 1H), 3.84 (t, *J* = 11.2 Hz, 1H), 3.31 (tdd, *J* = 9.6, 5.8, 4.1 Hz, 1H), 3.18 (dd, *J* = 16.4, 5.8 Hz, 1H), 3.07 (dd, *J* = 16.4, 9.2 Hz, 1H), 2.35 (s, 3H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 153.34, 151.21, 142.73, 137.63, 136.16, 129.39, 128.91, 128.80, 127.41, 127.16, 126.34, 125.61, 125.39, 124.42, 121.88, 51.11, 40.34, 34.27, 21.47.

HRMS (ESI): *m/z* calcd for C₂₃H₂₂O₂N⁺ [M + H]⁺ 344.1645 found 344.1641.

IR (ν_{max}/cm⁻¹) 1723, 1508, 1494, 1455, 1385, 1335, 1269, 1199, 1164, 1119, 752, 701, 645.

SFC Conditions: Chiralpak IC; Gradient 1; 92.5:7.5 er (major enantiomer *t_R* = 4.94 min; minor enantiomer *t_R* = 4.63 min), **85% ee**. [α]_D²⁵ = +8.2 (c = 2.0, CHCl₃).





Phenyl-(S)-6-methoxy-3-phenyl-3,4-dihydroquinoline-1(2H)-carboxylate (3au):



The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and phenyl 6-methoxyquinoline-1(2H)-carboxylate. The mixture was stirred at 30 °C for 48 hours. Purification by flash chromatography (5% acetone/petrol to 25% acetone/petrol) afforded compound **3au** as viscous liquid (82% yield, 85% ee).


¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 7.76 (s, 1H), 7.39 – 7.27 (m, 7H), 7.19 (t, *J* = 7.4 Hz, 1H), 7.07 – 7.00 (m, 2H), 6.80 (dd, *J* = 9.0, 2.8 Hz, 1H), 6.73 (d, *J* = 2.8 Hz, 1H), 4.31 (dd, *J* = 12.7, 4.0 Hz, 1H), 3.86– 3.67 (m, 4H), 3.32 (tt, *J* = 9.4, 5.1 Hz, 1H), 3.19 (dd, *J* = 16.6, 5.8 Hz, 1H), 3.09 (dd, *J* = 16.6, 9.4 Hz, 1H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 156.3, 153.3, 151.2, 142.6, 131.1, 129.4, 128.9, 127.4, 127.2, 125.5, 125.2, 121.8, 115.4, 113.6, 112.2, 55.6, 51.0, 40.4, 34.9.

HRMS (ESI): *m/z* calcd for C₂₃H₂₁O₃N⁺ [M + H]⁺ 360.1594 found 360.1590.

IR (ν_{max}/cm⁻¹) 1719, 1503, 1386, 1318, 1272, 1194, 1164, 1118, 749, 701, 690, 645.

SFC Conditions: Chiralpak IB; Gradient 1; 92.5:7.5 er (major enantiomer *t_R* = 4.77 min; minor enantiomer *t_R* = 4.58 min), **85% ee**. [α]_D²⁵ = +9.0 (c = 2.0, CHCl₃).







Phenyl-(S)-6-bromo-7-methyl-3-phenyl-3,4-dihydroquinoline-1(2H)-carboxylate (3av): The corresponding compound was prepared following general procedure **A** using phenyl boronic acid and phenyl 6-bromo-7-methylquinoline-1(2H)-carboxylate. The mixture was stirred at 70 °C for 20 hours. Purification by flash chromatography (2% acetone/petrol to 25% acetone/petrol) afforded compound **3av** as viscous liquid (80% yield, 86% ee).

¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 7.84 (s, 1H), 7.41 – 7.27 (m, 8H), 7.25 – 7.20 (m, 1H), 7.02 (d, *J* = 8.0 Hz, 2H), 4.30 (ddd, *J* = 12.8, 4.0, 1.2 Hz, 1H), 3.88 (t, *J* = 11.1 Hz, 1H), 3.31 (tdd, *J* = 9.4, 5.8, 3.9 Hz, 1H), 3.17 (dd, *J* = 16.5, 5.8 Hz, 1H), 3.07 (dd, *J* = 16.5, 9.0 Hz, 1H), 2.40 (s, 3H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 153.1, 151.0, 142.1, 136.9, 135.8, 132.1, 129.4, 129.0, 128.6, 127.32, 127.3, 125.9, 125.7, 121.8, 119.9, 51.0, 39.8, 33.8, 22.9.

HRMS (ESI): *m/z* calcd for C₂₃H₂₁O₂NBr⁺ [M + H]⁺ 422.0750 found 422.0740.


IR (ν_{max}/cm⁻¹) 1724, 1492, 1383, 1203, 1163, 757, 700.

SFC Conditions: Chiralpak ID; Gradient 1; 93:7 er (major enantiomer *t_R* = 4.59 min; minor enantiomer *t_R* = 4.98 min), **86% ee**. [α]_D²⁵ = +45.8 (c = 2.0, CHCl₃).



4. Derivatization of Chiral Tetrahydropyridines

Synthesis of trisubstituted piperidine (**4**):




A solution of N-bromosuccinimide (75 mg, 0.42 mmol) in methanol (1 mL) was added to a solution of dihydropyridine **3a** (58 mg, 0.21 mmol) in DCM (1 mL) at 0 °C then the mixture was allowed to warm to room temperature. After 16 h, the mixture was poured into a saturated aqueous solution of NaHCO₃. The aqueous phase was extracted three times with DCM and the solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel (5% acetone/petrol to 20% acetone/petrol) affording **4** (86% yield, 4:1 dr) as yellow oil.

¹H NMR (CDCl₃, 500 MHz) (2 rotamers * 2 diastereomers): δ (ppm) 7.44 – 7.10 (m, 10H), 5.75 – 5.58 (m, 1H), 4.56 – 4.12 (m, 2H), 3.61 – 3.37 (m, 4H), 3.32 – 3.07 (m, 1H), 2.71 – 2.54 (m, 1H), 2.46 – 2.11 (m, 1H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers, peak picked major diastereomer): δ (ppm) 154.8, 154.4, 151.3, 151.2, 141.6, 141.5, 129.5, 129.4, 128.9, 128.8, 127.5, 127.34, 127.26, 125.8, 125.6, 121.9, 121.7, 85.4, 84.7, 55.8, 55.4, 49.3, 48.7, 45.1, 44.3, 36.7, 36.3, 34.0, 33.9. **[α]_D²⁵** = +42.5 (c = 2.0, CHCl₃).

HRMS (ESI): m/z calcd for C₁₉H₂₁O₃NBr⁺ [M + H]⁺ 390.0699 found 390.0721.

IR (ν_{max}/cm⁻¹) 2935, 1726, 1596, 1495, 1455, 1415, 1351, 1267, 1206, 1163, 1069, 941, 876, 833, 756, 729, 701, 689.

Access towards (-) Preclamol:




A solution of dihydropyridine (0.5 mmol) in MeOH (1 mL) was added to a vial containing Pd/C (20 wt.%) in EtOAc (1 mL). The reaction mixture was purged with hydrogen (1 atm) balloon and stirred at room temperature. After 15 min of purging, the mixture was stirred under hydrogen atmosphere for 4 h. Upon completion of reaction, the mixture was diluted with Et₂O (5 mL) before passing through a plug of celite. The plug was washed with additional 10 mL of Et₂O and the solvents were removed in vacuo. Purification by flash chromatography (2% acetone/petrol to 20% acetone/petrol) afforded protected piperidine as viscous liquid.

A sealed flask protected piperidine (obtained above) and KOH (5 mmol, 10 equiv) in EtOH (3 mL) and H₂O (1 mL) was heated at 100 °C. After 18h, the mixture was warmed to room


temperature and diluted with H₂O (10 mL). The aqueous layer was extracted with DCM (2 × 10 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filtered, and the solvent was removed in vacuo to afford the corresponding amine.

The hydrochloride salts were isolated by adding 4N HCL (in dioxane) to the solution of corresponding amine in DCM (2 ml). After 15 minutes, the mixture was diluted with Et₂O (15 ml), precipitated solid was filtered then dried under vacuum to provide the corresponding product as off white solid.




Phenyl (S)-3-phenyl piperidine-1-carboxylate (S13): The corresponding compound was prepared following the procedure described above using dihydropyridine (**3a**) as viscous liquid. **¹H NMR** (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 7.42 – 7.06 (m, 10H), 4.48 – 4.25 (m, 2H), 3.12 – 2.75 (m, 3H), 2.17 – 2.07 (m, 1H), 1.94 – 1.83 (m, 1H), 1.81 – 1.58 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 153.8, 151.6, 143.1, 129.3, 128.7, 127.2, 126.9, 125.3, 121.9, 51.4, 51.0, 45.2, 44.7, 43.0, 42.5, 31.7, 25.9, 25.4. [α]²⁵_D = -78.3 (c = 2.0, CHCl₃).

IR (ν_{\max} /cm⁻¹) 2936, 1719, 1595, 1495, 1425, 1256, 1234, 1199, 1163, 1127, 1072, 1026, 981, 907, 831, 749, 701, 689, 670.




(S)-3-Phenylpiperidine hydrochloride salt (5): The corresponding compound was prepared following the procedure described as yellow solid (76% yield over 2 steps). **¹H NMR** (500 MHz, CDCl₃): δ (ppm) 9.73– 7.17 (m, 2H), 7.35 – 7.17 (m, 5H), 3.67 – 3.45 (m, 2H), 3.27 (t, *J* = 12.2 Hz, 1H), 2.92 (dq, *J* = 22.4, 11.4, 10.9 Hz, 2H), 2.14 (dd, *J* = 33.3, 14.1 Hz, 2H), 2.00 (d, *J* = 14.1 Hz, 1H), 1.73 – 1.61 (m, 1H). **¹³C NMR** (126 MHz, CDCl₃) δ 140.9, 129.0, 127.6, 127.0, 49.4, 44.1, 39.6, 30.4, 22.7. [α]²⁵_D = +6.7 (c = 0.3, CH₃OH). The spectroscopic data satisfactorily matched previously reported data.⁴



Phenyl (S)-3-(3-methoxyphenyl) piperidine-1-carboxylate (S14): The corresponding compound was prepared following the procedure described above using dihydropyridine (**3r**) as viscous liquid. **¹H NMR** (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 7.40 – 7.34 (m, 2H), 7.30 – 7.10 (m, 4H), 6.92 – 6.77 (m, 3H), 4.50 – 4.26 (m, 2H), 3.82 (s, 3H), 3.09 – 2.75 (m, 3H), 2.16 – 2.06 (m, 1H), 1.93 – 1.83 (m, 1H), 1.78 – 1.66 (m, 2H). **¹³C NMR** (126 MHz, CDCl₃)

(2 rotamers): δ (ppm) ^{13}C NMR (126 MHz, CDCl_3) δ 159.9, 153.9, 151.6, 144.8, 129.7, 129.3, 125.3, 121.9, 119.5, 113.4, 113.2, 112.0, 111.8, 55.3, 51.3, 50.9, 45.2, 44.7, 43.0, 42.7, 31.7, 31.6, 25.8, 25.3. $[\alpha]^{25}_{\text{D}} = -59.8$ ($c = 2.0$, CHCl_3).

HRMS (ESI): m/z calcd for $\text{C}_{19}\text{H}_{22}\text{O}_3\text{N}^+$ $[\text{M} + \text{H}]^+$ 312.1594 found 312.1605.



(S)-3-(3-methoxyphenyl) piperidine (6): The corresponding compound was prepared following the procedure described above as yellow oil (72% yield over 2 steps).


(6): ^1H NMR (400 MHz, CDCl_3): δ (ppm) 10.02 – 9.36 (m, 2H), 7.25 – 7.15 (m, 1H), 6.83 – 6.67 (m, 3H), 3.76 (s, 3H), 3.49 (t, $J = 10.2$ Hz, 2H), 3.20 (tt, $J = 12.5, 3.5$ Hz, 1H), 2.89 (q, $J = 16.7, 14.2$ Hz, 2H), 2.23 – 1.89 (m, 3H), 1.62 (qd, $J = 12.5, 3.2$ Hz, 1H). $[\alpha]^{25}_{\text{D}} = +10.6$ ($c = 1.0$, CH_3OH). The spectroscopic data satisfactorily matched previously reported data.⁴⁻⁶

(6.HCl): ^1H NMR (500 MHz, CDCl_3): δ (ppm) 9.98 – 9.40 (m, 2H), 7.25 – 7.15 (m, 1H), 6.83 – 6.67 (m, 3H), 3.76 (s, 3H), 3.49 (t, $J = 10.2$ Hz, 2H), 3.20 (tt, $J = 12.6, 3.5$ Hz, 1H), 2.89 (q, $J = 16.7, 14.2$ Hz, 2H), 2.23 – 1.89 (m, 3H), 1.62 (qd, $J = 12.6, 3.2$ Hz, 1H). **^{13}C NMR** (126 MHz, CDCl_3) δ 160.0, 142.5, 130.0, 119.2, 112.91, 112.85, 55.3, 49.2, 44.0, 39.7, 30.3, 22.7. $[\alpha]^{25}_{\text{D}} = +8.6$ ($c = 2.1$, CH_3OH). The spectroscopic data satisfactorily matched previously reported data.⁴⁻⁶


HRMS (ESI): m/z calcd for $\text{C}_{12}\text{H}_{18}\text{ON}^+$ $[\text{M} + \text{H}]^+$ 192.1383 found 192.1396.

IR ($\nu_{\text{max}}/\text{cm}^{-1}$) 2935, 2854, 2361, 1698, 1602, 1585, 1492, 1468, 1436, 1263, 1192, 1160, 1048, 856, 784, 754, 700.

Access towards Niraparib:



[Rh(PPh₃)₃Cl] (23 mg, 0.025 mmol, 5 mol%) was added to a 10 mL round bottom flask, sealed with a rubber septum, dissolved in THF (2 mL) and purged with hydrogen (1 atm) balloon while stirred at room temperature. After 10 min, a solution of **3k** (180 mg, 0.5 mmol, 1 equiv) in THF (2 mL) was added via syringe and again purged with hydrogen (1 atm) balloon while stirred at room temperature. After 15 min of purging, the mixture was stirred under hydrogen atmosphere for 18 h. Upon completion of reaction, the mixture was diluted with Et₂O (5 mL) before passing through a plug of silica. The plug was washed with additional 10 mL of Et₂O and the solvents were removed in vacuo. Purification by flash chromatography (5% acetone/petrol to 25% acetone/petrol) afforded protected piperidine as viscous liquid.




Phenyl (S)-3-(4-bromophenyl) piperidine-1-carboxylate (S15): ¹H NMR (CDCl₃, 500 MHz) (2 rotamers): δ (ppm) 7.48 – 7.42 (m, 2H), 7.39 – 7.32 (m, 2H), 7.20 (t, *J* = 7.3 Hz, 1H), 7.17 – 7.06 (m, 4H), 4.43 – 4.27 (m, 2H), 3.09 – 2.71 (m, 3H), 2.11 – 2.03 (m, 1H), 1.91 – 1.82 (m, 1H), 1.77 – 1.64 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) (2 rotamers): δ (ppm) 153.9, 151.5, 142.0, 131.8, 129.4, 129.0, 128.7, 127.8, 125.4, 121.9, 51.1, 50.7, 45.1, 44.6, 42.4, 42.0, 31.6, 25.8, 25.2. [α]²⁵_D = –84.3 (c = 2.0, CHCl₃).

HRMS (ESI): *m/z* calcd for C₁₈H₁₉O₂BrN⁺ [M + H]⁺ 360.0594 found 360.0611.

IR (ν_{max}/cm⁻¹) 2940, 2860, 2361, 1722, 1594, 1492, 1465, 1426, 1255, 1235, 1208, 1164, 1129, 1075, 1010, 982, 818, 754, 717, 691.

A sealed flask containing protected piperidine **S15** (obtained above) and KOH (5 mmol, 10 equiv) in EtOH (3 mL) and H₂O (1 mL) was heated at 100 °C. After 18h, the mixture was warmed to room temperature and diluted with H₂O (10 mL). The aqueous layer was extracted with DCM (2 × 10 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filtered, and the solvent was removed in vacuo to afford the corresponding amine (**7**) as yellow oil (82 mg, 68% yield over 2 steps).

The hydrochloride salts were isolated by adding 4N HCL (in dioxane) to the solution of corresponding amine in DCM (2 ml). After 15 minutes, the mixture was diluted with Et₂O (15 ml), precipitated solid was filtered then dried under vacuum to provide the corresponding product as off white solid (94 mg, 68% yield over 2 steps).



(7): ¹H NMR (500 MHz, CDCl₃): δ (ppm) 7.36 – 7.29 (m, 2H), 7.06 – 6.97 (m, 2H), 3.04 (t, *J* = 11.8 Hz, 2H), 2.59 – 2.48 (m, 3H), 1.93 – 1.82 (m, 1H), 1.71 (dt, *J* = 9.1, 2.5 Hz, 1H), 1.65 – 1.41 (m, 3H). [α]²⁵_D = +8.7 (*c* = 1.0, CH₃OH). The spectroscopic data satisfactorily matched previously reported data.^{7,8}

(7.HCl): ¹H NMR (500 MHz, CDCl₃): δ (ppm) 9.77 (d, *J* = 99.8 Hz, 1H), 7.44 (d, *J* = 8.3 Hz, 2H), 7.06 (d, *J* = 8.3 Hz, 2H), 3.50 (q, *J* = 13.8, 13.3 Hz, 2H), 3.23 (t, *J* = 12.3 Hz, 1H), 2.86 (q, *J* = 11.8 Hz, 2H), 2.25 – 1.93 (m, 4H), 1.67 – 1.55 (m, 1H). **¹³C NMR** (126 MHz, CDCl₃) δ 139.76, 132.18, 128.74, 121.52, 49.14, 43.97, 39.13, 30.25, 22.65. [α]²⁵_D = +4.3 (*c* = 1.0, CH₃OH).



HRMS (ESI): *m/z* calcd for C₁₁H₁₅BrN⁺ [M + H]⁺ 240.0382 found 240.0392.

IR (ν_{\max} /cm⁻¹) 2933, 2856, 2361, 1697, 1490, 1468, 1438, 1257, 1237, 1202, 1137, 1076, 1010, 982, 818, 769, 818, 754, 717, 691.


5. References

- (1) Kohari, Y.; Okuyama, Y.; Kwon, E.; Furuyama, T.; Kobayashi, N.; Otuki, T.; Kumagai, J.; Seki, C.; Uwai, K.; Dai, G.; Iwasa, T.; Nakano, H. Enantioselective Diels-Alder Reaction of 1,2-Dihydropyridines with Aldehydes Using β -Amino Alcohol Organocatalyst. *J. Org. Chem.* **2014**, *79* (20), 9500–9511.
- (2) Krow, G. R.; Huang, Q.; Szczepanski, S. W.; Hausheer, F. H.; Carroll, P. J. Stereoselectivity in Diels-Alder Reactions of Diene-Substituted N-Alkoxy carbonyl-1,2-Dihydropyridines. *J. Org. Chem.* **2007**, *72* (9), 3458–3466.
- (3) Heusler, A.; Fliege, J.; Wagener, T.; Glorius, F. Substituted Dihydropyridine Synthesis by Dearomatization of Pyridines. *Angew. Chemie Int. Ed.* **2021**, *60* (25), 13793–13797.
- (4) Colpaert, F.; Mangelinckx, S.; De Kimpe, N. Asymmetric Synthesis of Chiral N -Sulfinyl 3-Alkyl- and 3-Arylpiperidines by α -Alkylation of N -Sulfinyl Imidates with 1-Chloro-3-Iodopropane. *J. Org. Chem.* **2011**, *76* (1), 234–244.
- (5) Amat, M.; Cantó, M.; Llor, N.; Escolano, C.; Molins, E.; Espinosa, E.; Bosch, J. Dynamic Kinetic Resolution of Racemic γ -Aryl- δ -Oxoesters. Enantioselective Synthesis of 3-Arylpiperidines. *J. Org. Chem.* **2002**, *67* (15), 5343–5351.
- (6) Zhang, S. J.; Sun, W. W.; Yu, Q. Y.; Cao, P.; Dong, X. P.; Wu, B. Stereoselective Synthesis of (–)-3-PPP through Palladium-Catalysed Unactivated C(Sp³)–H Arylation at the C-3 Position of l-Pipecolinic Acid. *Tetrahedron Lett.* **2017**, *58* (7), 606–609.
- (7) Wallace, D. J.; Baxter, C. A.; Brands, K. J. M.; Bremeyer, N.; Brewer, S. E.; Desmond, R.; Emerson, K. M.; Foley, J.; Fernandez, P.; Hu, W.; Keen, S. P.; Mullens, P.; Muzzio, D.; Sajonz, P.; Tan, L.; Wilson, R. D.; Zhou, G.; Zhou, G. Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor. *Org. Process Res. Dev.* **2011**, *15* (4), 831–840.
- (8) Chung, C. K.; Bulger, P. G.; Kosjek, B.; Belyk, K. M.; Rivera, N.; Scott, M. E.; Humphrey, G. R.; Limanto, J.; Bachert, D. C.; Emerson, K. M. Process Development of C-N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymmetric Synthesis of Niraparib. *Org. Process Res. Dev.* **2014**, *18* (1), 215–227.



6. NMR Spectra




¹H NMR (400 MHz, CDCl₃) of **S10**





¹³C NMR (101 MHz, CDCl₃) of **S10**




¹H NMR (400 MHz, CDCl₃) of **S11**





¹³C NMR (101 MHz, CDCl₃) of **S11**




¹H NMR (400 MHz, CDCl₃) of **S12**





¹³C NMR (101 MHz, CDCl₃) of **S12**




¹H NMR (400 MHz, CDCl₃) of **3a**






¹³C NMR (101 MHz, CDCl₃) of **3a**





¹H NMR (400 MHz, CDCl₃) of **3b**




¹³C NMR (101 MHz, CDCl₃) of **3b**






$^1\text{H NMR}$ (400 MHz, CDCl_3) of **3d**





$^{13}\text{C NMR}$ (101 MHz, CDCl_3) of **3d**


May13-2022-36-SM-9-26.2.fid





^{19}F NMR (376 MHz, CDCl_3) of **3d**




¹H NMR (400 MHz, CDCl₃) of 3e






¹³C NMR (101 MHz, CDCl₃) of 3e




¹H NMR (400 MHz, CDCl₃) of **3f**





¹³C NMR (101 MHz, CDCl₃) of **3f**




Jul20-2022-36-SM-9-94R.3.fid





^{19}F NMR (376 MHz, CDCl_3) of **3g**




¹H NMR (400 MHz, CDCl₃) of 3h



¹³C NMR (101 MHz, CDCl₃) of 3h




¹H NMR (500 MHz, CDCl₃) of **3i**








¹³C NMR (126 MHz, CDCl₃) of **3i**

SM-9-108r.3.fid




^{19}F NMR (471 MHz, CDCl_3) of **3i**








¹H NMR (400 MHz, CDCl₃) of **3k**





¹³C NMR (101 MHz, CDCl₃) of **3k**





¹H NMR (500 MHz, CDCl₃) of **31**




¹³C NMR (126 MHz, CDCl₃) of **31**










^1H NMR (500 MHz, CDCl_3) of **3n**




^{13}C NMR (126 MHz, CDCl_3) of **3n**






¹H NMR (500 MHz, CDCl₃) of 3p





¹³C NMR (126 MHz, CDCl₃) of 3p


SM-9-91e.3.fid





^{19}F NMR (471 MHz, CDCl_3) of **3p**




¹H NMR (500 MHz, CDCl₃) of 3q





¹³C NMR (101 MHz, CDCl₃) of 3q




¹H NMR (400 MHz, CDCl₃) of **3r**





¹³C NMR (126 MHz, CDCl₃) of **3r**




¹H NMR (400 MHz, CDCl₃) of **3s**





¹³C NMR (101 MHz, CDCl₃) of **3s**




¹H NMR (500 MHz, CDCl₃) of 3t



¹³C NMR (126 MHz, CDCl₃) of 3t




¹H NMR (500 MHz, CDCl₃) of **3u**





¹³C NMR (126 MHz, CDCl₃) of **3u**


SM-9-105e.3.fid





^{19}F NMR (471 MHz, CDCl_3) of **3u**




¹H NMR (500 MHz, CDCl₃) of 3v





¹³C NMR (126 MHz, CDCl₃) of 3v




¹H NMR (400 MHz, CDCl₃) of **3w**





¹³C NMR (126 MHz, CDCl₃) of **3w**




^1H NMR (500 MHz, CDCl_3) of **3x**




^{13}C NMR (126 MHz, CDCl_3) of **3x**





¹H NMR (500 MHz, CDCl₃) of 3y




¹³C NMR (101 MHz, CDCl₃) of 3y





^{19}F NMR (471 MHz, CDCl_3) of **3y**




¹H NMR (400 MHz, CDCl₃) of **3z**





¹³C NMR (101 MHz, CDCl₃) of **3z**




^1H NMR (500 MHz, CDCl_3) of **3aa**



^{13}C NMR (126 MHz, CDCl_3) of **3aa**




¹H NMR (500 MHz, CDCl₃) of 3b





¹³C NMR (126 MHz, CDCl₃) of 3b


SM-9-109e.3.fid



^{19}F NMR (471 MHz, CDCl_3) of **3ab**




¹H NMR (400 MHz, CDCl₃) of 3ac








¹³C NMR (126 MHz, CDCl₃) of 3ac

SM-9-110.3




^{19}F NMR (471 MHz, CDCl_3) of **3ac**








¹H NMR (400 MHz, CDCl₃) of **3ae**




¹³C NMR (101 MHz, CDCl₃) of **3ae**





^{19}F NMR (471 MHz, CDCl_3) of **3ae**




¹H NMR (500 MHz, CDCl₃) of **3af**





¹³C NMR (126 MHz, CDCl₃) of **3af**




¹H NMR (400 MHz, CDCl₃) of 3ag





¹³C NMR (101 MHz, CDCl₃) of 3ag




¹H NMR (400 MHz, CDCl₃) of 3ah




¹³C NMR (101 MHz, CDCl₃) of 3ah





^1H NMR (500 MHz, CDCl_3) of **3ai**




^{13}C NMR (126 MHz, CDCl_3) of **3ai**




^{19}F NMR (471 MHz, CDCl_3) of **3ai**





¹H NMR (500 MHz, CDCl₃) of **3aj**




¹³C NMR (126 MHz, CDCl₃) of **3aj**





^{19}F NMR (471 MHz, CDCl_3) of **3aj**




¹H NMR (400 MHz, CDCl₃) of 3ak





¹³C NMR (101 MHz, CDCl₃) of 3ak




¹H NMR (400 MHz, CDCl₃) of **3al**






¹³C NMR (101 MHz, CDCl₃) of **3al**





¹H NMR (400 MHz, CDCl₃) of 3am




¹³C NMR (126 MHz, CDCl₃) of 3am








^1H NMR (400 MHz, CDCl_3) of **3ao**





^{13}C NMR (101 MHz, CDCl_3) of **3ao**




¹H NMR (400 MHz, CDCl₃) of 3ap





¹³C NMR (101 MHz, CDCl₃) of 3ap




¹H NMR (400 MHz, CDCl₃) of **3aq**





¹³C NMR (101 MHz, CDCl₃) of **3aq**




¹H NMR (400 MHz, CDCl₃) of **3as**





¹³C NMR (101 MHz, CDCl₃) of **3as**




¹H NMR (500 MHz, CDCl₃) of 3at





¹³C NMR (126 MHz, CDCl₃) of 3at




¹H NMR (500 MHz, CDCl₃) of 3au





¹³C NMR (126 MHz, CDCl₃) of 3au




¹H NMR (500 MHz, CDCl₃) of **3av**





¹³C NMR (126 MHz, CDCl₃) of **3av**




¹H NMR (500 MHz, CDCl₃) of **4**






¹³C NMR (126 MHz, CDCl₃) of **4**





¹H NMR (400 MHz, CDCl₃) of **S13**




¹³C NMR (101 MHz, CDCl₃) of **S13**








¹H NMR (400 MHz, CDCl₃) of S14




¹³C NMR (101 MHz, CDCl₃) of S14





^1H NMR (400 MHz, CDCl_3) of **6**




^1H NMR (400 MHz, CDCl_3) of **6.HCl**





^{13}C NMR (126 MHz, CDCl_3) of **6.HCl**




¹H NMR (500 MHz, CDCl₃) of S15



¹³C NMR (126 MHz, CDCl₃) of S15




^1H NMR (400 MHz, CDCl_3) of **7**



^1H NMR (500 MHz, CDCl_3) of **7.HCl**

SM-9-196HCl.2.fid



^{13}C NMR (126 MHz, CDCl_3) of **7.HCl**